UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Form 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2021~~2022


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-35420

ChemoCentryx, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	94-3254365
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

835 Industrial Road, Suite 600 San Carlos, California	94070
(Address of Principal Executive Offices)	(Zip Code)

(650) 210-2900

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CCXI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of ~~October~~April 29, ~~2021~~2022 was 7071,~~031~~193,~~462~~352.

CHEMOCENTRYX, INC.

QUARTERLY REPORT ON FORM 10-Q

For the quarterly period ended ~~September~~March 3031, ~~2021~~2022

Table of Contents

PART I. FINANCIAL INFORMATION		Page
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets – September 30, 2021 and December 31, 2020	3
	Condensed Consolidated Balance Sheets – March 31, 2022 and December 31, 2021	3
	Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2021 and 2020	4
	Condensed Consolidated Statements of Operations – Three Months Ended March 31, 2022 and 2021	4
	Condensed Consolidated Statements of Comprehensive Loss – Three and Nine Months Ended September 30, 2021 and 2020	5
	Condensed Consolidated Statements of Comprehensive Loss – Three Months Ended March 31, 2022 and 2021	5
	Condensed Consolidated Statements of Stockholders’ Equity – Three and Nine Months Ended September 30, 2021 and 2020	6
	Condensed Consolidated Statements of Stockholders’ Equity – Three Months Ended March 31, 2022 and 2021	6
	Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2021 and 2020	8
	Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2022 and 2021	7
	Notes to Condensed Consolidated Financial Statements	98
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	2627
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4329
Item 3.	Defaults Upon Senior Securities	4329
Item 4.	Mine Safety Disclosures	4329
Item 5.	Other Information	4329
Item 6.	Exhibits	4329
EXHIBIT INDEX		4430
SIGNATURES		4531

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value data)

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	9340,~~726~~577		$	3249,~~297~~978
Short-term investments		~~175~~300,~~701~~024			~~404~~214,~~273~~514
Accounts receivable from related party		20,005			32
Accounts receivable, net		2,781			411
Accounts receivable, other		52			137
Accounts receivable from related party		29			43
Prepaid expenses and other current assets		3,899			4,831
Inventory		2,897			851
Total current assets		293,383			441,570
Prepaid expenses and other current assets		5,324			3,380
Property and equipment, net		33,002			25,160
Total current assets		351,632			269,177
Long-term investments		102,030			23,800
Property and equipment, net		31,482			32,269
Operating lease right-of-use assets		25,035			26,911
Long-term investments		31,235			97,856
Other assets		1,395			1,458
Operating lease right-of-use assets		24,592			24,806
Total assets	$	454,845		$	518,899
Other assets		1,512			1,544
Total assets	$	440,453		$	425,652
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	45,~~414~~423		$	126,~~875~~746
Accrued and other current liabilities		25,~~984~~547			1926,~~794~~358
Long-term debt, current		1419,~~013~~128			618,~~302~~920
Deferred revenue from related party		1518,~~618~~709			1210,~~587~~993
Total current liabilities		6068,~~029~~807			5163,~~558~~017
Long-term debt, net		94,~~560~~554			184,~~099~~715
Non-current deferred revenue from related party		2162,~~423~~094			24,~~000~~772
Non-current lease liabilities		46,~~672~~062			3846,~~671~~830
Other non-current liabilities		~~1,267~~217			~~958~~198
Total liabilities		~~138~~181,~~951~~734			~~133~~139,~~286~~532
Commitments (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, $0.001 par value, 200,000,000 shares authorized; 69,937,510 and 69,452,466 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		70			69
Common stock, $0.001 par value, 200,000,000 shares authorized; 71,142,102 and 70,357,557 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively		71			70
Additional paid-in capital		~~892~~916,~~446~~224			~~870~~903,~~788~~646
Note receivable		(16	)		(16	)
Accumulated other comprehensive (loss) income		(37	)		114
Accumulated other comprehensive loss		(1,855	)		(483	)
Accumulated deficit		(~~576~~655,~~569~~705	)		(~~485~~617,~~342~~097	)
Total stockholders’ equity		~~315~~258,~~894~~719			~~385~~286,~~613~~120
Total liabilities and stockholders’ equity	$	~~454~~440,~~845~~453		$	~~518~~425,~~899~~652

See accompanying notes.

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

	Three Months EndedSeptember 30,						Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021			2020			2021			2020
	2022			2021
Revenue:
Collaboration and license revenue from related party	$	17,691		$	5,027		$	29,613		$	60,165
Product sales, net	$	5,353		$	—
Grant revenue		52			58			296			368
Collaboration and license revenue from related party		106			10,223
Total revenue		17,743			5,085			29,909			60,533
Grant revenue		—			130
Operating expenses:
Total revenue		5,459			10,353
Research and development		19,948			18,582			64,219			56,655
Operating expenses:
General and administrative		19,598			10,362			55,558			29,474
Cost of sales		205			—
Total operating expenses		39,546			28,944			119,777			86,129
Research and development		17,476			23,418
Loss from operations		(21,803	)		(23,859	)		(89,868	)		(25,596	)
Selling, general and administrative		26,011			16,262
Other expense:
Total operating expenses		43,692			39,680
Interest income		164			499			693			2,059
Loss from operations		(38,233	)		(29,327	)
Interest expense		(668	)		(700	)		(2,052	)		(1,943	)
Other expense:
Total other (expense) income, net		(504	)		(201	)		(1,359	)		116
Interest income		222			305
Net loss	$	(22,307	)	$	(24,060	)	$	(91,227	)	$	(25,480	)
Interest expense		(597	)		(689	)
Basic and diluted net loss per common share	$	(0.32	)	$	(0.35	)	$	(1.31	)	$	(0.40	)
Total other expense, net		(375	)		(384	)
Shares used to compute net loss per common share		69,894			68,922			69,764			64,500
Net loss	$	(38,608	)	$	(29,711	)
Net loss per common share
Basic and diluted net loss per common share	$	(0.55	)	$	(0.43	)
Shares used to compute basic and diluted net loss per common share		70,835			69,608

See accompanying notes.

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(unaudited)

	Three Months EndedSeptember 30,						Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021			2020			2021			2020
	2022			2021
Net loss	$	(2238,~~307~~608	)	$	(2429,~~060~~711	)	$	~~(91,227~~	)	$	~~(25,480~~	)
Unrealized gain (loss) on available-for-sale securities		44			(216	)		(151	)		(46	)
Unrealized loss on available-for-sale securities		(1,372	)		(128	)
Comprehensive loss	$	(2239,~~263~~980	)	$	(2429,~~276~~839	)	$	~~(91,378~~	)	$	~~(25,526~~	)

See accompanying notes.

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

(unaudited)

	Common Stock					AdditionalPaid-In			Note			AccumulatedOtherComprehensive			Accumulated			TotalStockholders'
	Shares			Amount		Capital			Receivable			Income (Loss)			Deficit			Equity
Balance as of June 30, 2021		69,885,975		$	70	$	884,559		$	(16	)	$	(81	)	$	(554,262	)	$	330,270
Balance as of December 31, 2021		70,357,557		$	70	$	903,646		$	(16	)	$	(483	)	$	(617,097	)	$	286,120
Net loss		—			—		—			—			—			(2238,~~307~~608	)		(2238,~~307~~608	)
Unrealized gain on investments		—			—		—			—			44			—			44
Unrealized loss on investments		—			—		—			—			(1,372	)		—			(1,372	)
Issuance of common stock under equity incentive plans		51,535			—		463			—			—			—			463
Issuance of common stock upon net exercise of warrant		66,833			—		—			—			—			—			—
Employee stock-based compensation		—			—		7,165			—			—			—			7,165
Issuance of common stock under equity incentive and employee stock purchase plans		803,567			1		6,278			—			—			—			6,279
Compensation expense related to options granted to consultants		—			—		259			—			—			—			259
Repurchased shares upon vesting of restricted stock units for tax withholdings		(85,855	)		—		(3,126	)		—			—			—			(3,126	)
Balance as of September 30, 2021		69,937,510		$	70	$	892,446		$	(16	)	$	(37	)	$	(576,569	)	$	315,894
Employee stock-based compensation		—			—		9,182			—			—			—			9,182
Compensation expense related to options granted to consultants		—			—		244			—			—			—			244
Balance as of March 31, 2022		71,142,102		$	71	$	916,224		$	(16	)	$	(1,855	)	$	(655,705	)	$	258,719

	Common Stock					AdditionalPaid-In			Note			AccumulatedOtherComprehensive			Accumulated			TotalStockholders'
	Shares			Amount		Capital			Receivable			Income (Loss)			Deficit			Equity
Balance as of December 31, 2020		69,452,466		$	69	$	870,788		$	(16	)	$	114		$	(485,342	)	$	385,613
Net loss		—			—		—			—			—			(9129,~~227~~711	)		(9129,~~227~~711	)
Unrealized loss on investments		—			—		—			—			(~~151~~128	)		—			(~~151~~128	)
Issuance of common stock under equity incentive plans		571,387			1		3,724			—			—			—			3,725
Issuance of common stock under equity incentive and employee stock purchase plans		370,987			1		2,162			—			—			—			2,163
Repurchased shares upon vesting of restricted stock units for tax withholdings		(8680,~~343~~960	)		—		(5,~~273~~013	)		—			—			—			(5,~~273~~013	)
Employee stock-based compensation		—			—		227,~~459~~840			—			—			—			227,~~459~~840
Compensation expense related to options granted to consultants		—			—		~~748~~240			—			—			—			~~748~~240
Balance as of September 30, 2021		69,937,510		$	70	$	892,446		$	(16	)	$	(37	)	$	(576,569	)	$	315,894
Balance as of March 31, 2021		69,742,493		$	70	$	876,017		$	(16	)	$	(14	)	$	(515,053	)	$	361,004

See accompanying notes.

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

(unaudited)

	Common Stock				AdditionalPaid-In		Note			AccumulatedOtherComprehensive			Accumulated			TotalStockholders'
	Shares		Amount		Capital		Receivable			Income (Loss)			Deficit			Equity
Balance as of June 30, 2020		68,803,400	$	69	$	852,006	$	(16	)	$	488		$	(431,406	)	$	421,141
Net loss		—		—		—		—			—			(24,060	)		(24,060	)
Unrealized loss on investments		—		—		—		—			(216	)		—			(216	)
Issuance of common stock under equity incentive plans		305,173		—		2,005		—			—			—			2,005
Employee stock-based compensation		—		—		5,721		—			—			—			5,721
Compensation expense related to options granted to consultants		—		—		228		—			—			—			228
Balance as of September 30, 2020		69,108,573	$	69	$	859,960	$	(16	)	$	272		$	(455,466	)	$	404,819

	Common Stock					AdditionalPaid-In			Note			AccumulatedOtherComprehensive			Accumulated			TotalStockholders'
	Shares			Amount		Capital			Receivable			Income (Loss)			Deficit			Equity
Balance as of December 31, 2019		60,234,784		$	60	$	495,624		$	(16	)	$	318		$	(429,986	)	$	66,000
Net loss		—			—		—			—			—			(25,480	)		(25,480	)
Unrealized loss on investments		—			—		—			—			(46	)		—			(46	)
Issuance of common stock upon follow-on offering, net of issuance costs		5,980,000			6		325,648			—			—			—			325,654
Issuance of common stock under equity incentive plans		2,986,248			3		26,495			—			—			—			26,498
Repurchased shares upon vesting of restricted stock units for tax withholdings		(92,459	)		—		(3,709	)		—			—			—			(3,709	)
Employee stock-based compensation		—			—		15,171			—			—			—			15,171
Compensation expense related to options granted to consultants		—			—		731			—			—			—			731
Balance as of September 30, 2020		69,108,573		$	69	$	859,960		$	(16	)	$	272		$	(455,466	)	$	404,819

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021			2020
	2022			2021
Operating activities
Net loss	$	(9138,~~227~~608	)	$	(2529,~~480~~711	)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation		239,~~207~~426			158,~~902~~080
Depreciation of property and equipment		21,~~123~~017			~~402~~117
Non-cash lease expense		~~1,375~~215			~~1,402~~594
Non-cash interest expense, net		31,~~713~~228			~~822~~997
Changes in assets and liabilities:
Accounts receivable, other		85			132
Accounts receivable, net		(2,370	)		7
Accounts receivable due from related party		(19,973	)		(58	)
Accounts receivable from related party		14			(9,980	)
Prepaids and other current assets		640			(770	)
Inventory		(2,046	)		—
Other assets		63			(5	)
Prepaids and other current assets		(2,162	)		583
Accounts payable		68			213
Other assets		32			(4	)
Operating lease liabilities		10,364			6,255
Accounts payable		(1,329	)		1,201
Other liabilities		4,374			(701	)
Operating lease liabilities		(664	)		6,342
Deferred revenue from related party		454			(60,033	)
Other liabilities		(960	)		418
Net cash used in operating activities		(64,734	)		(61,919	)
Deferred revenue from related party		45,038			(211	)
Net cash provided by (used in) operating activities		8,831			(21,567	)
Investing activities
Purchases of property and equipment, net		(~~18,527~~224	)		(610,~~136~~880	)
Purchases of investments		(~~246~~91,~~166~~498	)		(~~391~~95,~~942~~278	)
Maturities of investments		~~393~~70,~~453~~385			~~124~~166,~~220~~826
Net cash provided by (used in) investing activities		128,760			(273,858	)
Net cash (used in) provided by investing activities		(21,337	)		60,668
Financing activities
Proceeds from issuance of common stock		—			325,654
Proceeds from exercise of stock options and employee stock purchase plan		6,231			2,163
Proceeds from exercise of stock options and employee stock purchase plan		3,725			26,472
Employees' tax withheld and paid for restricted stock units		(3,126	)		(5,013	)
Employees' tax withheld and paid for with restricted stock units		(5,273	)		(3,709	)
Net cash provided by (used in) financing activities		3,105			(2,850	)
Borrowings under credit facility agreement, net of issuance costs		—			4,358
Net (decrease) increase in cash, cash equivalents and restricted cash		(9,401	)		36,251
Payments of long-term debt		(1,049	)		—
Cash, cash equivalents and restricted cash at beginning of period		51,058			33,377
Net cash (used in) provided by financing activities		(2,597	)		352,775
Cash, cash equivalents and restricted cash at end of period	$	41,657		$	69,628
Net increase in cash, cash equivalents and restricted cash		61,429			16,998
Cash, cash equivalents and restricted cash at beginning of period		33,377			40,259
Cash, cash equivalents and restricted cash at end of period	$	94,806		$	57,257
Supplemental disclosures of cash flow information
Cash paid for interest	$	~~1,534~~488		$	~~1,433~~509
Purchases of property and equipment, net recorded in accounts payable and accrued liabilities	$	8,562		$	7,175
Right-of-use assets obtained in exchange for lease obligations	$	1		$	300
Right-of-use assets obtained in exchange for lease obligations	$	501		$	27,365
Purchases of property and equipment, net recorded in accounts payable and accrued liabilities	$	6		$	2,807

See accompanying notes.

CHEMOCENTRYX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2021~~2022

(unaudited)

Description of Business

ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a fully integrated United States biopharmaceutical company focused on the development and commercialization of new medications targeting inflammatory disorders, autoimmune diseases and cancer. The Company discovered, developed and is now commercializing ~~TAVNEOSTM~~TAVNEOSÒ (avacopan) in the ~~United~~U.S. ~~States~~ as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoids use. The Company’s principal operations are in the ~~United~~U.S. ~~States~~ and it operates in one segment.

Unaudited Interim Financial Information

The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, ~~2020~~2021 Condensed Consolidated Balance Sheet was derived from audited financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 filed with the Securities and Exchange Commission on March 1, ~~2021~~2022.

Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

Concentration of Credit Risk

The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area.

For the three months ended March 31, 2022 and 2021, total revenue derived from the Company’s collaboration with Vifor (International) Ltd., and/or its affiliates, or collectively, Vifor, was 1.9% and 98.7%, respectively. Accounts receivable are typically unsecured and are concentrated within a few customers in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk.

Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents.

Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the sum of the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding for the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants, (ii) vesting of restricted stock units (RSUs) and restricted stock awards (RSAs), and (iii) the purchase from contributions to the amended and restated 2012 Employee Stock Purchase Plan (the Restated ESPP) (calculated based on the treasury stock method), are only included in the calculation of diluted net ~~income (~~loss) per share when their effect is dilutive.

For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021, the following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

	Three and Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2021		2020
	2022		2021
Options to purchase common stock, including purchases from contributions to ESPP		7,~~240~~123		7,~~416~~483
Restricted stock units		~~432~~560		~~389~~425
Restricted stock awards		15		14
Warrants to purchase common stock		150		150
Warrant to purchase common stock(1)		—		150
		7,837		7,969
		7,698		8,072

(1)

In 2012, the Company issued a warrant with a ten-year term to purchase 150,000 shares of its common stock at an exercise price of $20.00 per share. The warrant was exercised in January 2022.

Product Sales, net

The Company sells TAVNEOS to a limited number of specialty pharmacies and a specialty distributor. These customers subsequently dispense TAVNEOS directly to patients or resell it to hospitals and certain pharmacies. The Company recognizes product sales when the customer obtains control of the Company’s product, which occurs typically upon delivery to the customer. Product sales to these customers are recorded net of reserves established for distributor service fees and prompt payment discounts as stated in agreements, estimates for product returns, government rebates, chargebacks and the Company’s co-pay assistance program for patients. The Company estimates these reserves using the expected value approach. The Company believes its estimated reserves require significant judgment and may adjust these estimates as it accumulates historical data and assesses other quantitative and qualitative factors. Differences from actual results and changes to these estimates will be reported in the period that the differences become known.

Cost of Sales

Cost of sales for product sales and product supply consists primarily of direct and indirect costs related to the manufacturing of TAVNEOS products sold, including third-party manufacturing costs, packaging services, freight, storage costs, allocation of overhead costs of employees involved with production and net sales-based royalties expense. The Company began capitalizing costs related to inventory in October 2021 upon the U.S. Food and Drug Administration (FDA) approval of TAVNEOS. Manufacturing costs associated with campaigns initiated prior to FDA approval were recorded as research and development expense. Accordingly, cost of sales in the near term will likely be lower than in later periods given the sales of pre-approval inventory will carry little to no manufacturing costs given such costs were previously expensed to research and development expense.

Inventory

The Company values its inventories at the lower-of-cost or net realizable value on a first-in, first-out (FIFO) basis. Inventories include the cost for raw materials, third party contract manufacturing and packaging services, and indirect personnel and overhead associated with production. The Company performs an assessment of the recoverability of inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such impairment charges are recorded as a component of cost of sales in the consolidated statements of operations. The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company begins capitalizing costs as inventory when a drug candidate receives regulatory approval. Prior to regulatory approval, the Company recorded inventory costs related to drug candidates as research and development expense.

Comprehensive Loss

Comprehensive loss comprises net loss and other comprehensive loss. For the periods presented, other comprehensive loss consists of unrealized ~~gains (~~losses) on the Company’s available-for-sale securities. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021, there were no ~~significant~~ sales of investments and therefore there were no reclassifications of comprehensive loss.

Recent Accounting Pronouncements

The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.

Cash Equivalents, Restricted Cash and Investments

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Cash and cash equivalents	$	9340,~~726~~577	$	3249,~~297~~978
Restricted cash included in Other assets		1,080		1,080
Total cash, cash equivalents and restricted cash	$	9441,~~806~~657	$	3351,~~377~~058

Restricted cash as of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021 was held as collateral for stand-by letters of credit issued by the Company to its landlord in connection with the lease of the Company’s facility in San Carlos, California. See “Note 7. Commitments” for additional information on this lease.

Cash Equivalents and Investments

The amortized cost and fair value of cash equivalents and investments at ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021 were as follows (in thousands):

	September 30, 2021
	March 31, 2022
	Amortized		Gross Unrealized					Fair
	Cost		Gains		Losses			Value
Money market fund	$	8837,~~364~~331	$	—	$	—		$	8837,~~364~~331
U.S. treasury securities		40115,~~484~~369		61		(3708	)		40114,~~487~~662
Non-U.S. government securities		16,~~900~~743		—		(9180	)		16,~~891~~563
Commercial paper		8273,~~933~~868		—		—			8273,~~933~~868
Asset-backed securities		2532,~~002~~400		3—		(20212	)		2432,~~985~~188
Corporate debt securities		~~112~~94,~~449~~734		1514		(29770	)		~~112~~93,~~435~~978
Total available-for-sale securities	$	~~366~~370,~~132~~445	$	2415	$	(611,870	)	$	~~366~~368,~~095~~590
Classified as:
Cash equivalents								$	8837,~~364~~331
Short-term investments									~~175~~300,~~701~~024
Long-term investments									~~102~~31,~~030~~235
Total available-for-sale securities								$	~~366~~368,~~095~~590

	December 31, 2020
	Amortized		Gross Unrealized					Fair
	Cost		Gains		Losses			Value
Money market fund	$	30,139	$	—	$	—		$	30,139
U.S. treasury securities		176,625		60		—			176,685
Government-sponsored agencies		12,500		—		—			12,500
Commercial paper		140,364		—		—			140,364
Asset-backed securities		25,706		23		—			25,729
Corporate debt securities		72,764		38		(7	)		72,795
Total available-for-sale securities	$	458,098	$	121	$	(7	)	$	458,212
Classified as:
Cash equivalents								$	30,139
Short-term investments									404,273
Long-term investments									23,800
Total available-for-sale securities								$	458,212

Cash equivalents in the tables above exclude cash of $5.4 million and $2.2 million as of September 30, 2021 and December 31, 2020, respectively. All available-for-sale securities held as of September 30, 2021 had contractual maturities of less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented. The Company applies the specific identification method to determine the cost basis of the securities sold. No available-for-sale securities held as of September 30, 2021 have been in a continuous unrealized loss position for more than 12 months. As of September 30, 2021, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.


	December 31, 2021
	Amortized		Gross Unrealized					Fair
	Cost		Gains		Losses			Value
Money market fund	$	41,960	$	—	$	—		$	41,960
U.S. treasury securities		40,397		—		(160	)		40,237
Government-sponsored agencies		16,821		—		(56	)		16,765
Commercial paper		111,868		—		—			111,868
Asset-backed securities		39,988		—		(62	)		39,926
Corporate debt securities		103,779		7		(212	)		103,574
Total available-for-sale securities	$	354,813	$	7	$	(490	)	$	354,330

Classified as:
Cash equivalents								$	41,960
Short-term investments									214,514
Long-term investments									97,856
Total available-for-sale securities								$	354,330

Cash equivalents in the tables above exclude cash of $3.2 million and $8.0 million as of March 31, 2022 and December 31, 2021, respectively. All available-for-sale securities held as of March 31, 2022 had contractual maturities of less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented. The Company applies the specific identification method to determine the cost basis of the securities sold. No available-for-sale securities held as of March 31, 2022 have been in a continuous unrealized loss position for more than 12 months. As of March 31, 2022, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.

Fair Value Measurements

The Company determines the fair value of financial assets and liabilities using three levels of inputs as follows:

Level 1—Inputs which include quoted prices in active markets for identical assets and liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Recurring Fair Value Measurements

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows as of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021 (in thousands):

September 30, 2021

March 31, 2022

Description

Level 1

Level 2

Level 3

Total

Money market fund

8837,~~364~~331

—

8837,~~364~~331

U.S. treasury securities

—

40114,~~487~~662

—

40114,~~487~~662

Non-U.S. government securities

—

16,~~891~~563

—

16,~~891~~563

Commercial paper

—

8273,~~933~~868

—

8273,~~933~~868

Asset-backed securities

—

2432,~~985~~188

—

2432,~~985~~188

Corporate debt securities

—

~~112~~93,~~435~~978

—

~~112~~93,~~435~~978

Total available-for-sale securities

8837,~~364~~331

~~277~~331,~~731~~259

—

~~366~~368,~~095~~590

	December 31, 2020
Description	Level 1		Level 2		Level 3		Total
Money market fund	$	30,139	$	—	$	—	$	30,139
U.S. treasury securities		—		176,685		—		176,685
Government-sponsored agencies		—		12,500		—		12,500
Commercial paper		—		140,364		—		140,364
Asset-backed securities		—		25,729		—		25,729
Corporate debt securities		—		72,795		—		72,795
Total available-for-sale securities	$	30,139	$	428,073	$	—	$	458,212

During the three and nine months ended September 30, 2021, there were no transfers between Level 1 and Level 2 financial assets. When the Company uses observable market prices for identical securities that are traded in less active markets, the Company classifies its marketable debt instruments as Level 2. When observable market prices for identical securities are not available, the Company prices its marketable debt instruments using non-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar instruments; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated with observable market data. Non-binding market consensus prices are based on the proprietary valuation models of pricing providers or brokers. These valuation models incorporate a number of inputs, including non-binding and binding broker quotes; observable market prices for identical or similar securities; and the internal assumptions of pricing providers or brokers that use observable market inputs and, to a lesser degree, unobservable market inputs. The Company corroborates non-binding market consensus prices with observable market data using statistical models when observable market data exists. The discounted cash flow model uses observable market inputs, such as LIBOR-based yield curves, currency spot and forward rates, and credit ratings.


	December 31, 2021
Description	Level 1		Level 2		Level 3		Total
Money market fund	$	41,960	$	—	$	—	$	41,960
U.S. treasury securities		—		40,237		—		40,237
Government-sponsored agencies		—		16,765		—		16,765
Commercial paper		—		111,868		—		111,868
Asset-backed securities		—		39,926		—		39,926
Corporate debt securities		—		103,574		—		103,574
Total available-for-sale securities	$	41,960	$	312,370	$	—	$	354,330

During the three months ended March 31, 2022, there were no transfers between Level 1 and Level 2 financial assets. When the Company uses observable market prices for identical securities that are traded in less active markets, the Company classifies its marketable debt instruments as Level 2. When observable market prices for identical securities are not available, the Company prices its marketable debt instruments using non-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar instruments; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated with observable market data. Non-binding market consensus prices are based on the proprietary valuation models of pricing providers or brokers. These valuation models incorporate a number of inputs, including non-binding and binding broker quotes; observable market prices for identical or similar securities; and the internal assumptions of pricing providers or brokers that use observable market inputs and, to a lesser degree, unobservable market inputs. The Company corroborates non-binding market consensus prices with observable market data using statistical models when observable market data exists. The discounted cash flow model uses observable market inputs, such as LIBOR-based yield curves, currency spot and forward rates, and credit ratings.

Other Fair Value Measurements

The carrying amount and estimated fair value of financial instruments not recorded at fair value at ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021 were as follows (in thousands):

September 30,

December 31,

March 31,

December 31,

2021

2020

2022

2021

Carrying Amount

Estimated Fair Value

Carrying Amount

Estimated Fair Value

Long-term debt, net (1)

23,~~573~~682

2325,~~722~~170

2423,~~401~~635

25,~~332~~046

(1)

Carrying amounts of long-term debt were net of unamortized debt discounts of $~~378~~269 and $~~599~~316 as of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021, respectively.

The fair value of the Company's long-term debt is estimated using the net present value of future debt payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input.

Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Research and development related	$	911,~~805~~441	$	11,~~062~~309
Compensation related		104,~~356~~974		58,~~498~~350
Consulting and professional services		12,~~640~~127		1,~~690~~348
Current portion of operating lease liability		2,~~707~~915		~~845~~2,810
Other		1,476		699
End of term charge on the long-term debt		1,196		1,151
	$	25,984	$	19,794
Other		2,894		1,390
	$	25,547	$	26,358

Long-term Debt

In December 2017, the Company entered into a Loan and Security Agreement, with Hercules Capital, Inc. (Hercules), pursuant to which term loans in an aggregate principal amount of up to $50.0 million (as amended, the Credit Facility) were available to the Company. As of ~~September~~March 3031, ~~2021~~2022, the Company had borrowed $20.0 million under the Credit Facility, with an interest rate of 8.05% per annum and the remaining available amount had expired. Advances under the Credit Facility bear an interest rate equal to the greater of either (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal (the Prime Rate) minus 4.75%, and (ii) 8.05%. The Company made interest-only payments through June 2021 and the first principal and interest payment on July 1, 2021. The Credit Facility was subsequently amended in July 2021 and December 2021 to extend the interest-only payment period through ~~December~~August ~~2021~~1, 2022, and at which point the Company will then be obligated to repay the principal balance and interest on the advances in equal monthly installments through December 1, 2022. The Company is obligated to pay an end of term charge of $1.3 million in December 2022.

On January 8, 2020, the Company entered into an Amended and Restated Loan and Security Agreement (the Amended Loan Agreement) with Hercules, which amended and restated the agreement between the parties, and pursuant to which an additional term loan in an aggregate principal amount of up to $100.0 million (the Restated Credit Facility) is available to the Company at its discretion in three tranches. The first tranche of the Restated Credit Facility of up to $40.0 million was available to the Company through December 15, 2020, of which $20.0 million became available upon submission of the TAVNEOS New Drug Application (NDA) for the treatment of patients with ANCA-associated vasculitis. The second tranche of up to an additional $30.0 million ~~became~~was available to the Company through December 15, 2021 upon NDA approval of TAVNEOS for the treatment of ANCA-associated vasculitis. The third tranche of up to an additional $30.0 million would be available through December 15, 2022, subject to certain conditions.

Under the Restated Credit Facility, the Company borrowed $5.0 million from the first tranche with an interest rate of 8.50% per annum as of ~~September~~March 3031, ~~2021~~2022. Advances under the Restated Credit Facility bear an initial interest rate equal to the greater of either (i) 8.50% plus the Prime Rate minus 5.25%, and (ii) 8.50%, which may be reduced upon the Company achieving certain cumulative net TAVNEOS revenue levels. For advances under the Restated Credit Facility, the Company ~~will~~was required to make interest only payments through September 1, 2022 and ~~will then be obligated to~~ repay the principal balance and interest on the advances in equal monthly installments through February 1, 2024. ~~Upon~~However, upon satisfaction of certain conditions, the interest-only payment period and the principal balance repayment period may be extended. With the FDA approval of TAVNEOS in October 2021, the interest-only payment period and the principal balance repayment period was extended through March 1, 2023 and February 1, 2025, respectively. In addition, the Company iswill ~~obligated to~~ pay an end of term charge of 7.15% of the aggregate amount of the advances under the Restated Credit Facility in February 2025.

The Company paid a commitment fee of 1% of the advances made by Hercules, with a minimum charge of $162,500 for the Credit Facility and a minimum charge of $520,000 for the Restated Credit Facility. Also, the Company reimbursed Hercules for costs incurred related to the Restated Credit Facility. These charges were recorded as discounts to the carrying value of the loan and are amortized over the term of the loan using the effective interest method.

In addition, the Company may prepay advances under the ~~Amended~~Restated ~~Loan~~Credit ~~Agreement~~Facility, in whole or in part, at any time, subject to a prepayment charge that ranges from 1.0% to 2.0%, depending on the timing of the prepayment. The ~~Amended~~Restated ~~Loan~~Credit ~~Agreement~~Facility is secured by substantially all of the Company’s assets, excluding intellectual property. The ~~Amended~~Restated ~~Loan~~Credit ~~Agreement~~Facility also includes customary loan covenants, with which the Company was in compliance for all periods presented.

In connection with the Restated Credit Facility, the Company also entered into a Right to Invest Agreement with Hercules, pursuant to which Hercules shall have the right to participate, in an amount up to $3.0 million, in any subsequent equity financing broadly marketed to multiple investors in an amount greater than $30.0 million. Hercules purchased $1.0 million of the Company’s common stock during the June 2020 equity follow-on offering.

As of ~~September~~March 3031, ~~2021~~2022, the Company had outstanding borrowings under the Amended Loan Agreement of $23.67 million, net of discounts of $0.43 million. Future minimum principal payments, which exclude the end of term charge, as of ~~September~~March 3031, ~~2021~~2022 are as follows (in thousands):

	Amounts
Year ending December 31:
Remaining of fiscal year 2021	$	—
Remaining of fiscal year 2022	$	18,951
2022		20,006
2023		1,979
2023		3,353
2024		2,566
2024		592
2025		455
Total minimum payments		23,951
Less: amount representing debt discount		(~~378~~269	)
Present value of remaining debt payments		23,~~573~~682
Less: current portion		(1419,~~013~~128	)
Non-current portion	$	94,~~560~~554

Commitments

Purchase Obligations

The Company has entered into noncancelable agreements with vendors to secure raw materials and contract manufacturing organizations (CMOs) to manufacture its commercial supply of TAVNEOS. Some of these agreements contain binding commitment provisions for orders placed under purchase orders and forecasted quantities within a specified time frame. As of March 31, 2022, the Company’s noncancelable contractual obligations under these terms of the agreements are approximately $9.7 million. The Company enters into contracts in the normal course of business with CROs for clinical trials and with vendors for preclinical research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the purchase obligations above.

Operating Leases

In May 2004, the Company entered into a noncancelable operating lease for its previous office and primary research facility located in Mountain View, California. In May 2019, the Company entered into a third amendment to the lease agreement for the same facility to extend the term of the lease through April 2021. In July 2020, the Company entered into a letter agreement to further extend the lease term through June 2021.

In July 2019, the Company entered into a ten-year operating lease for a 96,463 square foot facility in San Carlos, California to replace its previous headquarters located in Mountain View, California. Upon execution of the lease agreement, the Company provided the landlord an approximately $1.1 million security deposit in the form of a letter of credit. The lease commenced in June 2020 and iswill ~~anticipated to~~ expire in February 2031 ~~with~~subject to an option to extend the lease for five years. The lease extension option was not considered in the right-of-use asset or the lease liability as the Company did not consider it reasonably certain the option would be exercised. Monthly rent payments began in March 2021. Following a six-month period of discounted rent, the Company is obligated to pay an initial annual base rent at a rate of approximately $6.5 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company moved its headquarters to this new facility in April 2021.

The Company was provided a tenant improvement allowance of $15.4 million plus an additional allowance of $4.8 million for the same. The additional allowance ~~will~~is be repaid by the Company as additional rent in equal monthly payments at a rate of 7% per annum through the initial term of the lease. As of ~~September~~March 3031, ~~2021~~2022, the Company ~~has~~ received atotal tenant improvement allowance of $1920.2 million. The Company has the right to sublease the facility, subject to landlord consent.

The balance sheet classification of the Company’s operating lease assets and liabilities was as follows (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Balance Sheet
Assets:
Operating lease right-of-use assets	$	2524,~~035~~592	$	2624,~~911~~806
Liabilities:
Operating lease liabilities:
Accrued and other current liabilities (1)	$	2,~~707~~915	$	~~845~~2,810
Non-current lease liabilities		46,~~672~~062		3846,~~671~~830

Includes current portion of operating lease liabilities as of September 30, 2021 and December 31, 2020.

The component of lease costs, which was included in operating expenses in the Company’s Condensed Consolidated Statements of Operations, was as follows (in thousands):

	Three Months EndedSeptember 30,				Nine Months EndedSeptember 30,
	2021		2020		2021		2020
Operating lease cost	$	1,375	$	1,743	$	4,857	$	2,905

(1)

~~During~~Includes ~~the~~current ~~nine-months~~portion ~~ended September 30, 2021 and 2020, cash paid for amounts included in the measurement~~ of operating lease liabilities ~~was $3~~.1 million, excluding the $10.0 million tenant improvement allowance received, and $1.2 million, respectively. These amounts were included in net cash used in operating activities in the Company’s Condensed Consolidated Statements of Cash Flows.

~~Future~~The ~~minimum~~component of lease ~~payments~~costs, ~~under~~which ~~all~~was ~~noncancelable~~included in operating ~~leases~~expenses asin ofthe ~~September~~Company’s ~~30,~~Condensed ~~2021~~Consolidated ~~are~~Statements of Operations, was as follows (in thousands):

	Operating leases
	Three Months EndedMarch 31,
Year ending December 31:
	2022			2021
Remaining of fiscal year 2021	$	1,816
Operating lease cost	$	1,375		$	1,742
2022		7,336
2023		7,535
2024		7,741
2025		7,952
Thereafter		44,686
Total minimum payments		77,066
Less: interest		(26,797	)
Less: future tenant improvement reimbursements		(890	)
Present value of lease liabilities	$	49,379

AsDuring ofthe ~~September~~three 30months ended March 31, 2022 and 2021, cash paid for amounts included in the ~~weighted-average~~measurement ~~remaining~~of lease ~~term~~liabilities was 9$2.420 ~~years~~million and $0.7 million, respectively, excluding the ~~weighted-average~~$0 ~~operating~~and ~~discount~~$5.9 ~~rate~~million tenant improvement allowance received in 2022 and 2021, respectively. These amounts were included in net cash used toin ~~determine~~operating activities in the ~~operating~~Company’s ~~lease~~Condensed ~~liability~~Consolidated ~~was~~Statements ~~9.5%.~~of Cash Flows.

Future minimum lease payments under all noncancelable operating leases as of March 31, 2022 are as follows (in thousands):


	Operating leases
Year ending December 31:
Remaining of fiscal year 2022	$	5,525
2023		7,535
2024		7,741
2025		7,952
2026		8,170
Thereafter		36,517
Total minimum payments		73,440
Less: interest		(24,463	)
Present value of lease liabilities	$	48,977

As of March 31, 2022, the remaining lease term was 8.9 years and the operating discount rate used to determine the operating lease liability was 9.5%.

Legal Proceedings

The Company is involved in a consolidated securities class action (Homyk v. ChemoCentryx, Inc., 4:21-cv-03343-JST (N.D. Cal.)) and a shareholder derivative action (Napoli v. Schall, 3:22-cv-00499 (N.D. Cal)), as discussed in the Legal Proceedings section within this Quarterly Report on Form 10-Q. The shareholder derivative action is stayed pending entry of judgment in the consolidated securities class action. Given the early stage of these cases, the Company is unable to estimate a range of potential loss, if any.

Related-Party Transactions

Vifor

Vifor held 95,194,085 shares of the Company’s common stock as of ~~September~~March 3031, ~~2021~~2022. The Company has collaboration agreements with Vifor: the Avacopan Agreements and the CCX140 Agreements (each as described below). See “Note 2. Summary of Significant Accounting Policies – Concentration of Credit Risk” for additional information on accounts receivable balance due from Vifor.

Avacopan Agreements

In May 2016, the Company entered into an exclusive collaboration and license agreement with Vifor pursuant to which the Company granted Vifor exclusive rights to commercialize avacopan in Europe and certain other markets (the Avacopan Agreement). Avacopan is the Company’s lead drug candidate for the treatment of patients with ANCA-associated vasculitis and other rare diseases. The Avacopan Agreement also provided Vifor with an exclusive option to negotiate during 2016 a worldwide license agreement for one of the Company’s other drug candidates, CCX140, an orally-administered inhibitor of the chemokine receptor known as CCR2. In connection with the Avacopan Agreement, the Company received a non-refundable upfront payment of $85.0 million, comprising $60.0 million in cash and $25.0 million in the form of an equity investment to purchase 3,333,333 shares of the Company’s common stock at a price of $7.50 per share.

In February 2017, Vifor and the Company expanded the Vifor territories under the Avacopan Agreement to include all markets outside the United States and China (the Avacopan Amendment). In connection with this February 2017 amendment, the Company received a $20.0 million upfront payment for the expanded rights. In June 2018, Vifor and the Company further expanded the Vifor territories under the Avacopan Agreement to provide Vifor with exclusive commercialization rights in China (the Avacopan Letter Agreement, and together with the Avacopan Agreement and the Avacopan Amendment, the Avacopan Agreements). The Company retains control of ongoing and future development of avacopan (other than country-specific development in the licensed territories) and all commercialization rights to avacopan in the United States. In consideration for the Avacopan Letter Agreement, the Company received a $5.0 million payment for the expanded rights.

In December 2017, the Company achieved a $50.0 million regulatory milestone when the European Medicines Agency (EMA) validated the Company’s conditional marketing authorization (CMA) application for avacopan for the treatment of ANCA-associated vasculitis. In February 2021, the Company achieved a $10.0 million regulatory milestone when the Japanese NDA (JNDA) for TAVNEOS in the treatment of ANCA-associated vasculitis was filed with the Japanese Pharmaceuticals and Medical Device Agency (PMDA) by Vifor, through its sublicensee Kissei Pharmaceutical, Co., Ltd. (Kissei). In September 2021, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the JNDA for TAVNEOS for the treatment of patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two main forms of ANCA-associated vasculitis. As a result, the Company achieved a $20.0 million regulatory milestone. Upon further achievement of certain regulatory and commercial milestones with

~~TAVNEOS~~In February 2017, Vifor and the Company ~~will~~expanded ~~receive~~the ~~additional~~Vifor ~~payments~~territories ofunder upthe Avacopan Agreement to include all markets outside the United States and China (the Avacopan Amendment). In connection with this February 2017 amendment, the Company received a $~~430~~20.0 million ~~under~~upfront payment for the ~~Avacopan~~expanded ~~Agreements~~rights. In ~~addition~~June 2018, Vifor and the Company ~~will~~further ~~receive~~expanded ~~royalties,~~the Vifor territories under the Avacopan Agreement to provide Vifor with ~~rates~~exclusive ~~ranging~~commercialization ~~from~~rights in China (the ~~low~~Avacopan ~~teens~~Letter toAgreement, and together with the ~~mid-twenties~~Avacopan Agreement and the Avacopan Amendment, onthe ~~future~~Avacopan ~~potential~~Agreements). ~~net~~The ~~sales~~Company retains control of ~~TAVNEOS~~ongoing byand ~~Vifor~~future development of avacopan (other than country-specific development in the licensed territories) and all commercialization rights to avacopan in the United States. In consideration for the Avacopan Letter Agreement, the Company received a $5.0 million payment for the expanded rights. In December 2017, the Company achieved a $50.0 million regulatory milestone when the European Medicines Agency (EMA) validated the Company’s conditional marketing authorization (CMA) application for avacopan for the treatment of ANCA-associated vasculitis.

~~The~~In ~~Company~~February ~~identified~~2021, the ~~following~~Company ~~material~~achieved ~~promises~~a ~~under~~$10.0 ~~the~~million ~~Avacopan~~regulatory ~~Agreements:~~milestone ~~(1)~~when the ~~license~~Japanese ~~related~~NDA ~~to avacopan;~~ (2JNDA) ~~the~~for ~~development~~TAVNEOS ~~and~~in ~~regulatory~~the ~~services~~treatment ~~for~~of ~~the~~ANCA-associated ~~submission~~vasculitis ofwas ~~the~~filed ~~marketing~~with ~~authorization~~the ~~application~~Japanese ~~(MAA);~~Pharmaceuticals and ~~(3)~~Medical anDevice ~~exclusive~~Agency ~~option~~(PMDA) toby ~~negotiate~~Vifor, athrough ~~worldwide~~its ~~license~~sublicensee ~~agreement~~Kissei ~~for~~Pharmaceutical, ~~CCX140~~Co., ~~which~~Ltd. ~~expired in 2016~~(Kissei). ~~The~~In ~~Company~~September ~~considered~~2021, ~~that~~ the ~~license~~Japanese ~~has~~Ministry ~~standalone functionality and is capable~~ of ~~being distinct. However~~Health, ~~the~~Labor ~~Company~~and ~~determined~~Welfare ~~that~~(MHLW) ~~the~~approved ~~license is not distinct from~~ the ~~development~~JNDA ~~and~~for ~~regulatory~~TAVNEOS ~~services~~for ~~within~~ the ~~context~~treatment of ~~the~~patients ~~agreement~~with ~~because~~microscopic ~~Vifor~~polyangiitis is(MPA) ~~dependent~~and ongranulomatosis ~~the~~with ~~Company~~polyangiitis to(GPA), ~~execute~~ the ~~development~~two ~~and~~main ~~regulatory~~forms ~~activities~~of inANCA-associated ~~order for Vifor to benefit from the license~~vasculitis. As ~~such~~a result, the ~~license~~Company isachieved ~~combined~~a ~~with~~$20.0 ~~the~~million ~~development and~~ regulatory ~~services into a single performance obligation~~milestone. ~~The~~In ~~exclusive~~November ~~option~~2021, ~~related to CCX140 is a separate performance obligation and~~ the ~~Company~~EMA ~~determined~~Committee ~~that~~for ~~its~~Medicinal ~~transaction~~Products ~~price~~for isHuman ~~not~~Use ~~material.~~(CHMP) ~~Therefore,~~adopted ~~the~~a ~~transaction~~positive ~~price~~opinion ~~under~~recommending ~~this~~marketing ~~arrangement~~authorization isfor ~~allocated to~~ the ~~license~~Company’s ~~and the development and regulatory services~~TAVNEOS.

AsIn January 2022, the European Commission approved TAVNEOS in combination with a rituximab or cyclophosphamide regimen for the treatment of ~~September~~adult 30patients with severe active MPA or GPA. Accordingly, ~~2021~~the Company achieved a $45.0 million regulatory milestone which the Company received in February 2022. Upon further achievement of certain regulatory and commercial milestones with TAVNEOS, the ~~transaction~~Company ~~price~~will receive additional payments of up to $~~183~~385.0 million ~~comprised~~under the ~~following:~~Avacopan Agreements. In addition, the Company will receive royalties, with rates ranging from the low teens to the mid-twenties, on future potential net sales of TAVNEOS by Vifor in the licensed territories.

The Company identified the following material promises under the Avacopan Agreements: (1) the license related to avacopan; (2) the development and regulatory services for the submission of the marketing authorization application (MAA); and (3) an exclusive option to negotiate a worldwide license agreement for CCX140, which expired in 2016. The Company considered that the license has standalone functionality and is capable of being distinct. However, the Company determined that the license is not distinct from the development and regulatory services within the context of the agreement because Vifor is dependent on the Company to execute the development and regulatory activities in order for Vifor to benefit from the license. As such, the license is combined with the development and regulatory services into a single performance obligation. The exclusive option related to CCX140 is a separate performance obligation and the Company determined that its transaction price is not material. As such, the transaction price under this arrangement is allocated to the license and the development and regulatory services.

As of March 31, 2022, the transaction price of $228.0 million comprised the following:

•

$78.0 million upfront payment under the May 2016 Avacopan Agreement. Of the total $85.0 million upfront payment received under the May 2016 Avacopan Agreement, $7.0 million was allocated to the issuance of 3,333,333 shares of the Company’s common stock valued at $2.10 per share, the closing stock price on the effective date of the agreement, May 9, 2016. The remaining $78.0 million was allocated to the transaction price under this arrangement;

•

$20.0 million upfront payment under the February 2017 Avacopan Amendment;

•

$50.0 million regulatory milestone payment achieved upon the validation of the Company’s CMA application by the EMA, for avacopan for the treatment of ANCA-associated vasculitis in December 2017;

•

$1030.0 million regulatory milestone ~~payment~~payments achieved upon the acceptance and the approval of the JNDA for TAVNEOS in the treatment of ANCA-associated vasculitis filed by Vifor, through its Japanese sublicensee Kissei with the PMDA in ~~February~~ 2021;

•

$2045.0 million regulatory milestone payment achieved upon the ~~MHLW~~European ~~approval~~Commission ofapproving ~~the~~TAVNEOS ~~JNDA~~in ~~for~~combination ~~TAVNEOS~~with ina rituximab or cyclophosphamide regimen for the treatment of ~~ANCA-associated~~adult ~~vasculitis~~patients bywith ~~Vifor,~~severe ~~through~~active ~~its~~MPA ~~Japanese~~or ~~sublicensee~~GPA ~~Kissei~~ in ~~September 2021~~2022; and

•

$5.0 million non-refundable upfront payment under the Avacopan Letter Agreement.

The Company ~~determined that the combined performance obligation~~ will bere-evaluate ~~performed over~~ the ~~duration~~transaction ofprice ~~the~~in ~~contract,~~each ~~which~~reporting ~~began~~period ~~on the effective date of May 9, 2016~~ and ~~ends~~as ~~upon~~uncertain ~~completion~~events ofare ~~development~~resolved ~~and~~or regulatory services. The Company uses a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because other ~~measures~~changes doin ~~not~~circumstances ~~reflect how the Company transfers its performance obligation to Vifor~~occur. In applying the cost-based input method of revenue recognition, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

~~For~~The ~~the~~Company ~~three~~determined ~~and~~that ~~nine~~the ~~months~~combined ~~ended~~performance ~~September~~obligation ~~30,~~will ~~2021,~~be ~~the~~performed ~~Company~~over ~~recognized~~the ~~$17.9~~duration ~~million~~of ~~and~~the ~~$28.2 million~~contract, ~~respectively,~~which ofbegan ~~collaboration~~on ~~and~~the ~~license~~effective ~~revenue~~date ~~under~~of ~~the~~May ~~Avacopan Agreements~~9, as2016 ~~compared~~and toends ~~$2.9~~upon ~~million~~completion ~~and~~of ~~$9.9~~development ~~million,~~and ~~respectively,~~regulatory ~~during~~services. ~~the~~The ~~same~~Company ~~periods~~uses ina ~~2020.~~

Avacopan Commercial Supply Agreement

In October 2020, the Company entered into a Manufacturing and Supply Agreement with Vifor (the Avacopan Commercial Supply Agreement). Under the Avacopan Commercial Supply Agreement, the Company will supply and sell avacopan drug product to Vifor for commercial use outside of the United States. Vifor will purchase avacopan drug product at a certain percentage mark up to the Company’s cost of goods, in accordance with the Avacopan Agreements. Vifor’s purchase of avacopan drug product is subject to certain binding forecast periods. The Avacopan Commercial Supply Agreement will expire upon the termination of the Avacopan Agreements or under certain circumstances as specified in the Avacopan Commercial Supply Agreement. In connection with the Avacopan Commercial Supply Agreement, the Company also entered into a letter agreement with Vifor, pursuant to which the $6.2 million previously received from Vifor under the CCX140 Agreement (discussed below) is creditable to Vifor’s purchase of avacopan drug product. For the nine months ended September 30, 2021, the Company recognized $0.6 million of collaboration and license revenue under the Avacopan Commercial Supply Agreement.

cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Vifor. In applying the cost-based input method of revenue recognition, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

For the three months ended March 31, 2022, the Company recognized $0.1 million of collaboration and license revenue under the Avacopan Agreements, as compared to $9.9 million during the same period in 2021.

Avacopan Commercial Supply Agreement

In October 2020, the Company entered into a Manufacturing and Supply Agreement with Vifor (the Avacopan Commercial Supply Agreement). Under the Avacopan Commercial Supply Agreement, the Company supplies and sells TAVNEOS to Vifor and its sublicensees for commercial use outside of the United States. Vifor will purchase TAVNEOS at a certain percentage mark up to the Company’s cost of goods, in accordance with the Avacopan Agreements. Vifor’s purchase of TAVNEOS is subject to certain binding forecast periods. The Avacopan Commercial Supply Agreement will expire upon the termination of the Avacopan Agreements or under certain circumstances as specified in the Avacopan Commercial Supply Agreement. In connection with the Avacopan Commercial Supply Agreement, the Company also entered into a letter agreement with Vifor, pursuant to which the $6.2 million previously received from Vifor under the CCX140 Agreement (discussed below) is creditable to Vifor’s purchase of TAVNEOS. For the three months ended March 31, 2022 and 2021, no product supply revenue was recognized under the Avacopan Commercial Supply Agreement.

CCX140 Agreements

In December 2016, the Company entered into a second collaboration and license agreement with Vifor pursuant to which the Company granted Vifor exclusive rights to commercialize CCX140 (the CCX140 Agreement) in markets outside the United States and China. CCX140 is an orally-administered inhibitor of the chemokine receptor known as CCR2. The Company retains marketing rights in the United States and China, while Vifor has commercialization rights in the rest of the world. Pursuant to the CCX140 Agreement, the Company is responsible for the clinical development of CCX140 in rare renal diseases and is reimbursed for Vifor’s equal share of such development cost. Under the terms of the CCX140 Agreement, the Company received a non-refundable upfront payment of $50.0 million in 2017.

In June 2018, the Company and Vifor entered into a letter agreement to expand Vifor’s rights to include the right to exclusively commercialize CCX140 in China (the CCX140 Letter Agreement). In connection with the CCX140 Letter Agreement, the Company received a non-refundable payment of $5.0 million. The Company and Vifor also entered into an amendment to the CCX140 Agreement (the CCX140 Amendment, and together with the CCX140 Agreement and the CCX140 Letter Agreement, the CCX140 Agreements) to clarify the timing of certain payments with respect to development funding of the CCX140 program by Vifor, and the Company received a non-refundable payment of $11.5 million. The Company retains control of ongoing and future development of CCX140 (other than country-specific development in the licensed territories), and all commercialization rights to CCX140 in the United States.

The Company identified the following material promises under the CCX140 Agreements: (1) the license related to CCX140; and (2) the development and regulatory services for the submission of the MAA. The Company considered that the license has standalone functionality and is capable of being distinct. However, the Company determined that the license is not distinct from the development and regulatory services within the context of the agreement because Vifor is dependent on the Company to execute the development and regulatory activities in order for Vifor to benefit from the license. As such, the license is combined with the development and regulatory services into a single performance obligation.

As of ~~September~~March 3031, ~~2021~~2022, the transaction price of $66.5 million comprised the following:

•

$50.0 million upfront payment under the CCX140 Agreement;

•

$11.5 million of CCX140 development funding by Vifor; and

•

$5.0 million non-refundable upfront payment under the CCX140 Letter Agreement.

The Company determined that the combined performance obligation will ~~re-evaluate~~be performed over the ~~transaction~~duration ~~price~~of inthe ~~each~~contract, ~~reporting~~which ~~period~~began on the effective date of December 22, 2016 and asends ~~uncertain~~upon ~~events~~completion ~~are~~of ~~resolved~~development orservices. ~~other~~The ~~changes~~Company inuses ~~circumstances~~a ~~occur~~cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The

The Company determined that the combined performance obligation will be performed over the duration of the contract, which began on the effective date of December 22, 2016 and ends upon completion of development services. The Company uses a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Vifor. In applying the cost-based input method of revenue recognition, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

In May 2020, the Company announced topline data from a 46 patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS), called the LUMINA-1 trial. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment. As such, CCX140 will not be further developed in FSGS. As a result, the Company reduced the total anticipated FSGS budgeted costs and the corresponding transaction price related to development funding under the CCX140 Agreement by $47.2 million and recognized $46.7 million of contract revenue during the three months ended June 30, 2020. In addition, $6.2 million of deferred revenue previously received from Vifor under the CCX140 Agreements is creditable against Vifor’s purchases of avacopan drug product under the Avacopan Commercial Supply Agreement. Vifor retains an option to solely develop and commercialize CCX140 in more prevalent forms of chronic kidney disease (CKD). Should Vifor later exercise the CKD option, the Company would receive co-promotion rights for CKD in the United States.

For the three and nine months ended September 30, 2021, the Company recognized $7,000 and $0.8 million of collaboration and license revenue under the CCX140 Agreements, respectively, compared to $2.1 million and $50.2 million during the same periods in 2020, respectively. As of September 30, 2021, deferred revenue under the CCX140 Agreement, representing the Company’s remaining estimated performance obligation under these agreements has been fully recognized.

Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Vifor. In applying the cost-based input method of revenue recognition, the Company measures actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

In May 2020, the Company announced topline data from a 46 patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS), called the LUMINA-1 trial. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment. As such, CCX140 will not be further developed in FSGS. As a result, the Company reduced the total anticipated FSGS budgeted costs and the corresponding transaction price related to development funding under the CCX140 Agreement by $47.2 million and recognized $46.7 million of contract revenue during the three months ended June 30, 2020. In addition, $6.2 million of deferred revenue previously received from Vifor under the CCX140 Agreements is creditable against Vifor’s purchases of TAVNEOS under the Avacopan Commercial Supply Agreement. Vifor retains an option to solely develop and commercialize CCX140 in more prevalent forms of chronic kidney disease (CKD). Should Vifor later exercise the CKD option, the Company would receive co-promotion rights for CKD in the United States.

The Company fully recognized collaboration and license revenue under the CCX140 Agreements in 2021. Accordingly, no revenue was recognized during the three months ended March 31, 2022 compared to $0.3 million during the three months ended March 31, 2021.

The following table presents the contract assets and liabilities for all of the Company’s revenue contracts as of the following dates (in thousands):

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
Contract asset:
Accounts receivable	$	~~20,005~~29		$	3243
Contract liability:
Deferred revenue	$	(3780,~~041~~803	)	$	(3635,~~587~~765	)

During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, the Company recognized the following revenue as a result of changes in the contract asset and the contract liability balances (in thousands):

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021		2021
	2022		2021
Revenue recognized in the period from:
Amount included in contract liability at the beginning of the period	$	~~17,682~~—	$	2910,~~546~~211
Performance obligations satisfied (or partially satisfied) in previous periods	$	162,~~313~~254	$	248,~~391~~443

Government Grant

In September 2019, the Company was awarded a two-year $1.0 million grant from the orphan drug office of the U.S. Food and Drug Administration to support the clinical development of ~~avacopan~~TAVNEOS in patients with the rare kidney disease complement 3 glomerulopathy (C3G). The grant was extended for an additional four months in August 2021. ~~For~~and the ~~three~~grant ~~and~~revenue ~~nine~~was ~~months~~fully ~~ended~~recognized ~~September~~in ~~30,~~ 2021. Accordingly, ~~the~~no ~~Company~~revenue was recognized ~~$0.1~~during ~~million~~the ~~and~~three months ended March 31, 2022 compared to $0.41 million ofin ~~grant~~the ~~revenue,~~same ~~respectively~~period of 2021. As of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021, $~~52,000~~0 and $~~0.1 million~~28,000 ~~respectively,~~ was recorded as accounts receivable., respectively.

10.

Stockholders’ Equity

Stock Options

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, the Company had the following activities under its equity incentive plans:

		Availablefor Grant			Shares			Weighted AverageExercisePrice		Weighted AverageRemainingContractualTerm (in years)		AggregateIntrinsic Value
Balance at December 31, 2020			3,170,577			7,114,225		$	14.61
Balance at December 31, 2021			5,641,782			6,767,895		$	19.14
	Shares authorized		~~2,950,000~~—			—
	Granted (1)		(1,~~198~~624,~~068~~830	)		~~945~~1,~~534~~082,730			5329.64
	Exercised (2)		~~86,343~~—			(~~324~~604,~~204~~083	)		10.3039
	Forfeited and expired		~~537~~145,~~592~~939			(~~537~~145,~~592~~939	)		2741.7527
Outstanding at September 30, 2021			5,546,444			7,197,963		$	18.95		5.89	$	243,375,474
Outstanding at March 31, 2022			4,162,891			7,100,603		$	21.03		6.22	$	74,672,588
Vested and expected to vest, net of estimated forfeiture at September 30, 2021						6,988,419		$	18.23		5.81	$	240,345,856
Vested and expected to vest, net of estimated forfeiture at March 31, 2022						6,785,124		$	20.36		6.08	$	74,199,516
Exercisable at September 30, 2021						5,099,071		$	11.17		4.89	$	204,903,335
Exercisable at March 31, 2022						4,672,389		$	13.93		4.73	$	68,152,545

(1)

The difference between shares granted in the number of shares available for grant and outstanding options represents the RSUs and RSAs granted for the period with a 1. 5 share ratio reduction to the reserve shares for each RSU or RSA grant in accordance with the amended and restated 2012 Equity Incentive Award Plan.

(2)

Shares presented as available for grant represents shares repurchased for tax withholding upon vesting of RSUs.

Restricted Stock

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, the activity for restricted stock is summarized as follows:

	Shares			~~WeightedAverageGrant~~WeightedAverage Grant-~~DateFair~~Date Fair Value
Balance at December 31, 2020		420,030		$	34.73
Balance at December 31, 2021		413,510		$	45.94
Granted		~~229~~361,~~356~~400			5429.5883
Vested		(~~202~~199,~~342~~484	)		3043.6062
Canceled		—			—
Unvested at March 31, 2022		575,426		$	36.63
Unvested at September 30, 2021		447,044		$	46.79

Stock-based Compensation

Total stock-based compensation expense was $79.4 million ~~and $23.2 million~~ during the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, ~~respectively,~~ and $58.91 million ~~and $15.9 million~~ during the same ~~periods~~period ended ~~September~~March 3031, ~~2020, respectively~~2021. As of ~~September~~March 3031, ~~2021~~2022, $4250.30 million, $1115.62 million and $~~84,000~~0.1 million of total unrecognized compensation expenses associated with outstanding employee stock options, unvested restricted stock, and the ESPP, net of estimated forfeitures, respectively, were expected to be recognized over a weighted-average period of 2.349, 12.438 and 0.121 years, respectively.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, filed with the Securities and Exchange Commission, or SEC, on March 1, ~~2021~~2022.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “aim,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential” or “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•

the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;

•

our ability to advance drug candidates into, and successfully complete, clinical trials;

•

the anticipated impact of the ongoing pandemic of novel coronavirus disease 2019, or COVID-19, ~~pandemic~~and its variants on our business, preclinical studies, ~~clinical trials~~ and ~~ability~~clinical ~~to commercialize any of our drug candidates~~trials;

•

the commercialization of TAVNEOSTM (avacopan) and our other drug candidates;

the implementation of our business model, strategic plans for our business, drug candidates and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology;

•

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

•

the timing or likelihood of regulatory filings and approvals;

•

our ability to maintain and establish collaborations or obtain additional government grant funding;

•

the impact or outcome of putative shareholder class action or putative shareholder derivative litigation;

•

the global economic and political environments;

•

our financial performance; and

•

developments relating to our competitors and our industry.

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, filed with the SEC on March 1, ~~2021~~2022.

Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

ChemoCentryx®, the ChemoCentryx logo, and ~~TAVNEOSTM~~TAVNEOSÒ are our trademarks in the United States, the European Community, Australia and Japan. EnabaLink® and RAM® are our trademarks in the United States. Each of the other trademarks, trade names or service marks appearing in this Quarterly Report on Form 10-Q belongs to its respective holder.

Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms “ChemoCentryx,” “we,” “us” and “our” refer to ChemoCentryx, Inc., a Delaware corporation, and our subsidiaries taken as a whole unless otherwise noted.

Overview

ChemoCentryx is a fully integrated United States biopharmaceutical company focused on the development and commercialization of new medications targeting inflammatory disorders, autoimmune diseases and cancer. We ~~have~~target ~~commercially~~the ~~launched~~chemokine ~~TAVNEOS~~and inchemoattractant systems to discover, develop and commercialize orally-administered therapies. In the ~~United~~U.S., ~~States~~we inmarket TAVNEOSÒ (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis, or ANCA-associated vasculitis, specifically granulomatosis with polyangiitis, or GPA, and microscopic polyangiitis, or MPA, the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use.

In October 2021, we obtained regulatory approval and launched TAVNEOS in the U.S. ~~Food~~for ~~and~~the ~~Drug~~treatment ~~Administration,~~of oran ~~FDA,~~orphan ~~approved~~disease ~~TAVNEOS~~called ANCA-associated vasculitis, anleading ~~orally~~to ~~administered~~the ~~selective~~recent ~~complement~~grant 5aof ~~receptor~~orphan ~~inhibitor,~~drug asmarketing anexclusivity ~~adjunctive~~for ~~treatment~~a period of seven years discussed further below. TAVNEOS also obtained regulatory approval in Japan for ~~adult~~the treatment of patients with ~~severe~~MPA ~~active~~and ~~ANCA-associated~~GPA ~~vasculitis~~in 2021. In January 2022, ~~specifically~~the ~~granulomatosis~~European Commission approved TAVNEOS in combination with ~~polyangiitis,~~a rituximab or ~~GPA,~~cyclophosphamide ~~and~~regimen ~~microscopic~~for ~~polyangiitis,~~the treatment of adult patients with severe active GPA or MPA,. ~~the~~TAVNEOS ~~two~~received ~~main~~marketing ~~forms~~authorization in all member states of ~~ANCA-associated~~the ~~vasculitis~~EU, as well as in ~~combination~~Iceland, ~~with~~Liechtenstein ~~standard~~and ~~therapy~~Norway. ~~ANCA-associated~~Also, ~~vasculitis~~in isJanuary a2022, ~~systemic~~the ~~autoimmune~~FDA ~~disease~~granted ina ~~which over~~seven-~~activation~~year oforphan ~~the~~drug ~~complement~~marketing ~~system~~exclusive ~~further~~approval ~~activates~~for ~~neutrophils,~~TAVNEOS ~~leading~~which tobegan ~~inflammation~~on ~~and~~October ~~eventual~~7, ~~destruction~~2021, the date of ~~small~~approval ~~blood~~of ~~vessels~~the NDA. ~~This~~We ~~results~~are inrequired ~~organ~~to ~~damage~~assure ~~and~~the ~~failure,~~availability ~~with~~of ~~the~~sufficient ~~kidney~~quantities asof ~~the~~TAVNEOS ~~major~~to ~~target,~~meet ~~and~~the isneeds ~~often~~of ~~fatal~~patients ifto ~~not~~maintain ~~treated~~exclusivity.

~~TAVNEOS~~ ANCA-associated vasculitis is ~~the~~a ~~first~~group ~~FDA~~of ~~approved~~rare ~~orally~~diseases that affect small-~~administered~~to-medium ~~inhibitor~~sized ofblood ~~the~~vessels ~~complement~~in 5athe ~~receptor~~patient’s body. It ~~The~~involves ~~approval~~inflammation inof ~~ANCA-associated~~the ~~vasculitis~~blood ~~was~~vessels, ~~supported~~which byreduces ~~the~~blood ~~results~~flow ofand ~~the~~can ~~pivotal~~result ~~Phase~~in ~~III~~organ ~~ADVOCATE~~damage ~~trial~~and failure, ~~which~~with ~~were~~the ~~highlighted~~kidney inas the ~~February~~major ~~2021~~target, ~~edition~~and ofis ~~The~~often ~~New~~fatal ~~England~~if ~~Journal~~not ~~of Medicine~~treated. WeWhile ~~have~~a ~~developed~~patient’s ~~TAVNEOS~~genetics ~~Connect,~~and aenvironment ~~patient~~are ~~support~~thought ~~program~~to ~~designed~~be tocontributing ~~assist~~causes ~~patients~~of ~~who~~the ~~are~~disease, ~~prescribed~~the ~~TAVNEOS~~exact cause is currently unknown.

We The ~~also~~two ~~plan~~most tocommon ~~commercialize~~sub-types ~~TAVNEOS~~of ~~internationally~~ANCA-associated ~~through~~vasculitis ~~our~~are ~~kidney~~GPA ~~health~~and ~~alliance~~MPA. ~~with~~In ~~Vifor~~GPA, ~~Fresenius~~small ~~Medical~~areas ~~Care~~of ~~Renal~~inflammation ~~Pharma~~called ~~Ltd.~~“granulomas” ~~and~~develop ~~its~~inside ~~affiliates~~parts ~~and~~of ~~sublicensees,~~the ~~or collectively, Vifor~~body. InGPA ~~November~~typically ~~2020,~~involves ~~Vifor announced that~~ the ~~Marketing~~kidneys, ~~Authorisation~~lungs, ~~Application~~ears, ornose ~~MAA,~~and ~~for~~throat. ~~TAVNEOS~~If ina ~~the~~patient ~~treatment~~has ofGPA ~~ANCA-associated~~they ~~vasculitis~~may ~~was~~be ~~accepted~~at risk for ~~review~~serious ~~(validated)~~complications, bysuch ~~the~~as ~~European~~hearing ~~Medicines Agency~~loss, orkidney ~~EMA.~~damage, ~~Decision~~skin onscarring, ~~the~~or ~~MAA~~blood ~~filing~~clots. isMPA ~~expected~~also byaffects the ~~end~~lungs ofand ~~2021~~kidneys. InHowever, ~~September~~unlike ~~2021~~GPA, ~~the~~a ~~Japanese~~patient’s ~~Ministry of Health~~ears, ~~Labor~~nose and ~~Welfare,~~throat orare ~~MHLW,~~less ~~approved~~likely ~~the~~to ~~Japanese~~be ~~NDA~~affected, ~~or JNDA, filed by Vifor~~ and ~~Kissei~~there ~~for~~is ~~TAVNEOS~~no ~~for~~granuloma ~~the treatment of patients with MPA and GPA~~formation.

We ~~Our~~plan ~~drug candidates are designed~~ to ~~selectively~~capitalize ~~block~~on aTAVNEOS’s ~~specific~~potential ~~chemoattractant~~to ~~receptor,~~address ~~leaving~~multiple ~~the~~disease ~~rest~~areas ofin the ~~immune~~coming ~~system intact~~years. ~~These~~We ~~drug~~consider ~~candidates~~TAVNEOS ~~are~~to ~~small~~be ~~molecules,~~a ~~orally-administered~~‘Pipeline ~~inhibitors~~in ~~that~~a ~~could address unmet medical needs, including improved efficacy, and offer significant quality of life benefits~~Drug.’ ~~Since~~We ~~patients~~plan ~~swallow~~to acontinue ~~capsule~~ or ~~pill~~initiate ~~instead~~clinical ofdevelopment ~~having~~in toadditional ~~visit~~rare adiseases, ~~clinic~~including ~~for~~severe anhidradenitis ~~infusion~~suppurativa, or ~~undergo an injection~~HS, ~~our~~complement ~~drug~~3 ~~candidates~~glomerulopathy, ~~may~~or ~~improve~~C3G, ~~patient~~and ~~compliance.~~lupus ~~Our~~nephritis, ~~pipeline~~or ~~includes the following programs:~~LN.

Our goal is to change treatment paradigms in orphan and rare disease; specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. Each of our drug candidates and our first commercial drug product, TAVNEOS:, are designed to selectively block a specific chemoattractant receptor. Separately, in our cancer program, we use a novel, orally-administered drug candidate, CCX559, designed to inhibit programmed death-ligand 1/programmed death protein 1, or PD-L1/PD-1, which we are developing for the treatment of a variety of cancers. Small molecule checkpoint inhibitors may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, and the convenience of oral administration.

WeHighlights are also developing TAVNEOS for the treatment of severe (Hurley Stage III) hidradenitis suppurativa, or HS. In October 2020, we announced topline data with positive results in a subgroup analysis of severe HS patients (Hurley Stage III) from ~~the~~our ~~Phase II AURORA trial of TAVNEOS. We plan to advance TAVNEOS into Phase III clinical~~ development ~~for~~pipeline ~~the treatment of severe HS in the first half of 2022.~~ include:

InTAVNEOSÒ December 2020, we announced topline data from the Phase II ACCOLADE trial of TAVNEOS for the treatment of patients with complement 3 glomerulopathy, or C3G. We plan to discuss the evidence of clinical benefit of TAVNEOS in C3G with the FDA in the first half of 2022.(avacopan):

•

~~Based~~We onare also developing TAVNEOS for the ~~renal~~treatment ~~improvement~~of ~~results~~severe ~~observed~~HS. ~~with~~We ~~TAVNEOS~~reported ~~treatment~~initial intopline ~~both~~data, ~~the~~including ~~ADVOCATE~~positive ~~trial~~results in ~~ANCA-associated~~a ~~vasculitis~~subgroup ~~and~~analysis ~~the~~of ~~ACCOLADE~~patients ~~trial~~with inHurley ~~C3G,~~Stage asIII ~~measured~~(considered byto anhave ~~increase~~severe inHS) ~~estimated~~from ~~glomerular~~the ~~filtration~~Phase ~~rate,~~II weAURORA ~~plan~~trial toof ~~develop~~ TAVNEOS; inhowever, ~~additional~~the ~~complement-mediated~~primary ~~renal~~efficacy ~~indications~~endpoint ~~such~~was asnot ~~lupus~~met ~~nephritis,~~in orthe LNoverall study population. WePending interactions with regulatory agencies, we plan to ~~initiate~~advance aTAVNEOS ~~clinical~~into ~~development~~Phase ~~towards~~III ~~registration~~clinical ofdevelopment ~~TAVNEOS~~ for the treatment of LNsevere HS in ~~mid-~~the second half of 2022.

•

~~Immuno~~We plan to develop TAVNEOS in additional complement-~~Oncology:~~mediated renal indications, such as LN. We plan to initiate a clinical development program for TAVNEOS in LN in the second half of 2022, pending interaction with regulatory agencies.

•

~~CCX559~~We isalso ~~our~~reported ~~orally-administered~~initial ~~small~~topline ~~molecule~~data ~~checkpoint~~from ~~(PD-1/PD-L1)~~the ~~inhibitor,~~Phase ~~which~~II weACCOLADE ~~are~~trial ~~developing~~of TAVNEOS for the treatment of ~~various~~patients ~~cancers~~with C3G. We ~~initiated~~plan ato ~~Phase~~review Idata ~~clinical~~from the ACCOLADE trial ofwith ~~CCX559~~FDA in ~~the~~ second ~~quarter~~half of ~~2021~~2022.

Immuno-Oncology

•

CCX559 is our orally-administered inhibitor for PD-L1/PD-1, which we are developing for the treatment of various cancers. This structurally novel small molecule displayed nanomolar potency and high selectivity for PD-L1. Results from in vitro studies suggested that CCX559 induced the dimerization and internalization of cell-surface PD-L1. CCX559, when orally administered in animal models, was observed to have anti-tumor activity, including the potential to induce complete responses. Safety pharmacology and toxicology studies in preclinical animal species supported the initiation of human trials in patients with advanced tumors. We initiated a Phase I dose escalation study of CCX559 in patients with advanced solid tumors in the second quarter of 2021. We plan to report initial data from this study in 2022 and initiate a Phase 1b/2 clinical study in selected patient populations in the second half of 2022.

Our Strategy

The key elements to our commercial and scientific strategy are to:

•

Commercialize TAVNEOS® (avacopan) in the United States onusing our own resources, where we believe a company of our size can effectively compete in rare disease markets. We have deployed a specialty sales force primarily targeting that subset of nephrologists and rheumatologists treating ANCA-associated vasculitis patients in the United States;

•

21Continue to develop CCX559, our orally-administered inhibitor for PD-L1/PD-1 for various cancers;

•

~~Support~~Develop ~~our international commercialization partner Vifor~~ and ~~its~~commercialize ~~Japanese~~TAVNEOS ~~sublicensee~~for ~~Kissei~~additional ~~Pharmaceutical~~indications, ~~Co.,~~including ~~Ltd.~~C3G, orsevere ~~Kissei~~HS, inand ~~their~~additional ~~regulatory~~complement-mediated ~~approval~~renal ~~applications.~~indications, ~~TAVNEOS~~such ~~was~~as ~~approved~~LN, inif ~~Japan in September 2021~~approved;

•

Develop ~~and~~our ~~commercialize~~drug ~~TAVNEOS~~candidates ~~for~~and ~~additional~~establish ~~indications,~~collaborations ~~including~~with ~~C3G,~~pharmaceutical ~~severe~~and ~~HS,~~biotechnology ~~and~~companies ~~additional~~to ~~complement-mediated~~further ~~renal~~develop ~~indications~~and ~~such~~market asour LNdrug candidates; and

•

~~Develop~~Discover ~~our other drug candidates~~ and ~~establish collaborations with pharmaceutical and biotechnology companies to further~~ develop ~~and~~new ~~market our~~ drug candidates;. ~~and~~

~~Discover~~As ~~and~~of ~~validate~~March ~~new~~31, 2022, we had an accumulated deficit of $655.7 million. We expect to continue to incur net losses as we continue to commercialize TAVNEOS in the United States, develop our drug candidates, expand clinical trials for our drug candidates currently in clinical development, and expand our research and development activities, organization systems and facilities. Significant capital is required to commercialize a drug product and many expenses are incurred before revenues are received. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

As of September 30, 2021, we had an accumulated deficit of $576.6 million. We expect to continue to incur net losses as we launch TAVNEOS in the United States, develop our other drug candidates, expand clinical trials for our drug candidates currently in clinical development, and expand our research and development activities, organization, systems and facilities. Significant capital is required to launch a drug product and many expenses are incurred before revenues are received. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

COVID-19

In December 2019, a disease caused by a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. This virus has spread globally, including countries in which we have active clinical trial sites or contract manufacturing sites. The length of the pandemic and its related restrictions and their consequences for us remain subject to a number of risks and uncertainties, including disease resurgence and variants. We experienced a delay in topline clinical data from our ongoing AURORA trial to the fourth quarter of 2020, due to COVID-19, impacting certain sites where the trial was being conducted. We do not currently anticipate any material delays in ~~the~~our ~~continued~~ commercial ~~launch~~production of TAVNEOS ~~in ANCA-associated vasculitis,~~ nor are we currently anticipating any material disruption in our clinical drug supply as a result of the pandemic. However, the pandemic continues to be unpredictable, and impacts may not be foreseeable or expected.

Critical Accounting Policies and Significant Judgments and Estimates

There have been no material changes in significant judgments and estimates for our critical accounting policies during the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, as compared to those disclosed in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, filed with the SEC on March 1, ~~2021~~2022.

Results of Operations

Revenue

We ~~have~~launched ~~not~~TAVNEOS ~~generated~~and ~~any~~began ~~revenue~~commercial ~~from drug product~~ sales. ~~For~~during the ~~periods~~quarter ~~presented,~~ended ~~our~~December ~~revenues were derived from collaboration and license revenue related to the Avacopan Agreement~~31, ~~the Avacopan Commercial Supply Agreement and the CCX140 Agreement, in each case, as amended, and the related letter agreements~~2021. Total revenue for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, as compared to the same ~~periods~~period in the prior year, was as follows (in thousands):

	Three Months EndedSeptember 30,					Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021			2020		2021			2020
	2022			2021
Collaboration and license revenue from related party	$	17,691		$	5,027	$	29,613		$	60,165
Product sales, net	$	5,353		$	—
Grant revenue		52			58		296			368
Collaboration and license revenue from related party		106			10,223
Total revenue	$	17,743		$	5,085	$	29,909		$	60,533
Grant revenue		—			130
Dollar increase (decrease)	$	12,658				$	(30,624	)
Total revenue	$	5,459		$	10,353
Percentage increase (decrease)		249	%				(51	%)
Dollar decrease	$	(4,894	)
Percentage decrease		(47	%)

WeFor ~~use~~the athree ~~cost-based~~months ~~input~~ended ~~method~~March to31, ~~measure~~2022, ~~proportional~~our ~~performance~~revenue ~~and~~was toprimarily ~~calculate~~derived ~~the~~from ~~corresponding~~TAVNEOS ~~amount~~sales, ofas ~~revenue~~compared to ~~recognize. In applying~~ the ~~cost-based~~collaboration ~~input~~and ~~method~~license of revenue ~~recognition,~~generated wein ~~measure~~the ~~actual~~same ~~costs~~period ~~incurred~~of ~~relative~~2021 torelated ~~budgeted costs~~ to ~~fulfill~~ the ~~combined~~Avacopan ~~performance~~Agreements ~~obligation.~~and ~~These~~the ~~costs~~CCX140 ~~primarily~~Agreement, ~~consist~~in ofeach ~~third-party~~case, ~~contract costs. Revenue is recognized based on actual costs incurred~~ as aamended, ~~percentage~~and ofthe ~~total~~related ~~budgeted~~letter ~~costs as we complete our performance obligations~~agreements.

~~The~~For ~~increase~~the incollaboration ~~total~~and license revenue, ~~during~~we use a cost-based input method to measure proportional performance and to calculate the ~~three~~corresponding ~~months~~amount ~~ended~~of ~~September~~revenue ~~30,~~to ~~2021~~recognize. ~~from~~In applying the ~~same~~cost-based ~~period~~input method of ~~2020~~revenue ~~was~~recognition, ~~attributable~~we measure actual costs incurred relative to budgeted costs to fulfill the ~~$20~~combined performance obligation.0 ~~million~~These ~~milestone~~costs ~~earned~~consist ~~from~~primarily ~~Vifor~~of ~~for~~third-party ~~the~~contract ~~September~~costs. ~~2021~~Revenue ~~JNDA,~~is ~~approval~~recognized bybased ~~the~~on ~~MHLW,~~actual ~~for~~costs ~~TAVNEOS~~incurred inas ~~the~~a percentage of total budgeted costs as we complete our performance obligations.

22The decrease in total revenue from 2021 to 2022 for the three months ended March 31 was attributable to the $10.0 million milestone received in 2021 from Vifor for the February 2021 acceptance of the Japanese NDA, for TAVNEOS in the treatment of ANCA-associated vasculitis, which subsequently led to the September 2021 Japanese NDA approval of TAVNEOS. The impact of the increase in transaction price of the Avacopan Agreements from the $45.0 million non-refundable regulatory milestone received upon TAVNEOS approval in Europe during the first quarter of 2022 was offset by the impact of an increase in the estimated underlying development budget (which also occurred in the quarter ended March 31, 2022 but was unrelated to the increase in the transaction price) and therefore is currently estimated to be recognized over a four year period, subject to adjustment from time to time, as performance obligations under the Avacopan Agreements are fulfilled. This overall decrease in revenue was partially offset by U.S. TAVNEOS net sales in 2022.

treatment of ANCA-associated vasculitis. The decrease in total revenue for the nine months ended September 30, 2021 was primarily due to the acceleration of revenue recognized under the CCX140 Agreement, reflecting the decision to discontinue development of CCX140 in FSGS in the second quarter of 2020. This decrease was partially offset by the $30.0 million milestones from Vifor for the February 2021 JNDA acceptance and the September 2021 JNDA approval of TAVNEOS. In addition, during the nine months ended September 30, 2021, we recognized $0.6 million of collaboration and license revenue related to sales of TAVNEOS to Vifor for anticipated commercial use outside of the United States.

Research and development expenses

Research and development expenses represent costs incurred to conduct basic research, discovery and development of novel small molecule therapeutics, development of our suite of proprietary drug discovery technologies, preclinical studies and clinical trials of our drug candidates. We recognize all research and development expenses as they are incurred. These expenses consist primarily of salaries and related benefits, including stock-based compensation, third-party contract costs relating to research, formulation, manufacturing, preclinical study and clinical trial activities, laboratory consumables, and allocated facility costs. Total research and development expenses for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, as compared to the same ~~periods~~period in the prior year, were as follows (in thousands):

	Three Months EndedSeptember 30,							Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021				2020			2021				2020
	2022				2021
Research and development expenses		$	1917,~~948~~476			$	1823,~~582~~418		$	~~64,219~~			$	~~56,655~~
Dollar increase		$	1,366						$	7,564
Dollar decrease		$	(5,942	)
Percentage increase			7	%						13	%
Percentage decrease			(25	%)

The ~~increases~~decrease from ~~2020~~2021 to ~~2021~~2022 for the three ~~and~~months ~~nine month periods~~ ended ~~September~~March 3031 ~~were~~was primarily attributable to the manufacture of commercial drug supply inwhich ~~anticipation~~was ofaccounted for as inventory in the ~~launch~~first quarter of ~~TAVNEOS~~2022 ~~for~~as compared to the ~~treatment~~same period of ~~ANCA-associated~~2021 ~~vasculitis~~in ~~and~~which ~~higher~~such ~~research~~costs ~~and~~were ~~drug~~expensed ~~discovery~~in ~~expenses,~~anticipation ~~including~~of ~~those~~the ~~associated~~launch ~~with~~of TAVNEOS for the ~~development~~treatment of ~~CCX559,~~ANCA-associated ~~our~~vasculitis. ~~orally-available~~Manufacturing ~~small~~costs ~~molecule~~associated ~~checkpoint~~with ~~(PD-1/PD-L1)~~campaigns ~~inhibitor.~~initiated ~~These~~prior ~~increases~~to FDA approval were ~~partially~~recorded ~~offset~~as byresearch ~~lower~~and development expense. Lower Phase II related expenses due to the completion of the TAVNEOS AURORA Phase IIb clinical trial in patients with HS ~~and~~also ~~the discontinuation of further clinical development of CCX140 in FSGS in 2020.~~

The following table summarizes our research and development expenses by project (in thousands):

	Three Months EndedSeptember 30,				Nine Months EndedSeptember 30,
	2021		2020		2021		2020
Phase I	$	3,239	$	25	$	9,301	$	455
Phase II		3,813		5,335		11,336		20,160
Phase III		7,825		5,769		27,212		18,995
Research and drug discovery		5,071		7,453		16,370		17,045
Total research and development expenses	$	19,948	$	18,582	$	64,219	$	56,655

We track development expenses that are directly attributable to our clinical development candidates by phase of clinical development. Such development expenses include third-party contract costs relating to formulation, manufacturing, preclinical studies and clinical trial activities. We allocate research and development salaries, benefits or indirect costs to our development candidates and we have included such costs in research and development expenses. All remaining research and development expenses are reflected in “Research and drug discovery” which represents early stage drug discovery programs. Such expenses include allocated employee salaries and related benefits, stock-based compensation, consulting and contracted services to supplement our in-house laboratory activities, laboratory consumables and allocated facility costs associated with these earlier stage programs.

At any given time, we typically have several active early stage research and drug discovery projects. Our internal resources, employees and infrastructure are not directly tied to any individual research or drug discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding these costs incurred for our early stage research and drug discovery programs on a project specific basis. We expect our research and development expenses to increase as we advance our development programs further and increase the number and size of our clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We, or our partners, may never succeed in achieving marketing approval, as we did with TAVNEOS, for any of our other drug candidates. The probability of success for each drug candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Our strategy includes entering into additional partnerships with third parties for the development and commercialization of some of our independent drug candidates.

contributed to the decrease. These decreases were partially offset by higher expenses, including those associated with the development of CCX559, our orally-available small molecule checkpoint (PD-L1/PD-1) inhibitor.

The following table summarizes our research and development expenses by stage of development (in thousands):


	Three Months Ended March 31,
	2022		2021
Phase I	$	2,671	$	17
Phase II		3,102		4,048
Phase III		7,487		10,910
Research and drug discovery		4,216		8,443
Total research and development expenses	$	17,476	$	23,418

At any given time, we typically have several active early stage research and drug discovery projects. Our internal resources, employees and infrastructure are not directly tied to any individual research or drug discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding these costs incurred for our early stage research and drug discovery programs on a project specific basis. We expect our research and development expenses to increase as we advance our development programs further and increase the number and size of our clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We, or our partners, may never succeed in achieving marketing approval, as we did with TAVNEOS, for any of our drug candidates. The probability of success for each drug candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Our strategy includes entering into additional partnerships with third parties for the development and commercialization of some of our independent drug candidates.

The successful development of our drug candidates is highly uncertain and may not result in approved drug products. Completion dates and completion costs can vary significantly for each drug candidate and are difficult to predict for each drug product. Given the uncertainty associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of the current or future clinical trials of our drug candidates or if, or to what extent, we will generate revenues from the commercialization and sale of any of our drug candidates. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each drug candidate, as well as ongoing assessment as to each drug candidate’s commercial potential. We may need to raise additional capital or may seek additional strategic alliances in the future in order to complete the development and commercialization of our drug candidates, including TAVNEOS, CCX559 and CCX507.

~~General~~Selling, general and administrative expenses

Total selling, general and administrative expenses for the three~~-and~~ ~~nine-~~months ended ~~September~~March 3031, ~~2021~~2022, as compared to the same ~~periods~~period in the prior year, were as follows (in thousands):

	Three Months EndedSeptember 30,							Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021				2020			2021				2020
	2022				2021
General and administrative expenses		$	19,598			$	10,362		$	55,558			$	29,474
Selling, general and administrative		$	26,011			$	16,262
Dollar increase		$	9,~~236~~749						$	~~26,084~~
Percentage increase			8960	%						88	%

~~General~~Selling, general and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation and travel expenses, in executive, finance, commercial, business and corporate development and other administrative functions, as well as costs associated with the launch and commercialization of TAVNEOS. Other selling, general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, legal costs of pursuing patent protection of our intellectual property, and professional fees for auditing, tax, and legal services.

The increases from 2020 to 2021 for the three and nine month periods ended September 30 were primarily due to higher employee-related expenses, including those associated with our commercialization planning efforts, and higher professional fees. We anticipate that our general and administrative expenses will increase substantially in the future primarily due to commercialization-related activities and personnel costs to support the launch of TAVNEOS in ANCA-associated vasculitis in the United States.

Other (expense) income, net

Other (expense) income, net primarily consists of interest income earned on our marketable securities and interest expense for our long-term debt. Total other (expense) income, net for the three and nine month periods ended September 30, 2021, as compared to the same periods in the prior year were as follows (in thousands):

	Three Months EndedSeptember 30,								Nine Months EndedSeptember 30,
	2021				2020				2021				2020
Interest income		$	164			$	499			$	693			$	2,059
Interest expense			(668	)			(700	)			(2,052	)			(1,943	)
Total other (expense) income, net		$	(504	)		$	(201	)		$	(1,359	)		$	116
Dollar increase		$	303							$	1,475
Percentage increase			151	%							1272	%

The increases in total other expense, net from 2020 to 2021 for the three and nine month periods ended September 30 were primarily due to less interest income earned from our investment portfolio under the continued low interest rate environment during the current COVID-19 pandemic and increased interest expense due to additional borrowings under the Credit Facility and the Restated Credit Facility (as defined below) in March 2020.

The increase from 2021 to 2022 for the three month period ended March 31 was primarily due to higher employee-related expenses and professional fees, including those associated with the U.S. launch and commercialization of TAVNEOS.

We anticipate that our selling, general and administrative expenses will increase substantially in the future primarily due to commercialization-related activities and personnel costs to support the commercialization of TAVNEOS as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis in the United States.

Other expense, net

Other expense, net primarily consists of interest income earned on our marketable securities and interest expense for our long-term debt. Total other expense, net for the three month period ended March 31, 2022, as compared to the same period in the prior year was as follows (in thousands):


	Three Months Ended March 31,
	2022				2021
Interest income		$	222			$	305
Interest expense			(597	)			(689	)
Total other expense, net		$	(375	)		$	(384	)
Dollar decrease		$	(9	)
Percentage decrease			(2	%)

The decrease from total other expense, net from 2021 to 2022 for the three months ended March 31 was primarily due to less interest expense and less interest income earned from lower cash and investment balances.

Liquidity and Capital Resources

As of ~~September~~March 3031, ~~2021~~2022, we had approximately $372.59 million in cash, cash equivalents, restricted cash and investments. The following table shows a summary of our cash flows for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021 (in thousands):

	Nine Months EndedSeptember 30,
	Three Months EndedMarch 31,
	2021				2020
	2022				2021
Cash provided by (used in)
Operating activities		$	~~(64~~8,~~734~~831	)		$	(6121,~~919~~567	)
Investing activities		$	~~128~~(21,~~760~~337	)		$	~~(273~~60,~~858~~668	)
Financing activities		$	(23,~~597~~105	)		$	~~352~~(2,~~775~~850	)

Operating activities. Net cash ~~used~~provided inby operating activities was $648.78 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, compared to $6121.96 million cash used for the same period in ~~2020~~2021. This increase was primarily due to changes in working capital items.

Investing activities. Net cash ~~provided by (~~used in) or provided by investing activities for periods presented primarily relate to the purchase, sale and maturity of investments used to fund the day-to-day needs of our business. ~~Following our equity follow-on offering in June 2020, we invested the majority of our net proceeds received in short and long term investments.~~

Financing activities. Net cash ~~used~~provided inby financing activities was $23.61 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, compared to cash ~~provided~~used in financing activities of $~~352~~2.89 million for the same period in ~~2020~~2021. Net cash ~~used~~provided inby financing activities for both periods presented included proceeds from the exercise of stock options and stock purchases from contributions to our amended and restated 2012 Employee Stock Purchase Plan, and cash used for tendered ChemoCentryx, Inc. common stock to satisfy employee tax withholding requirements upon vesting of restricted stock units. Net cash provided by financing activities for the nine months ended September 30, 2020 included net proceeds of $325.7 million from the issuance of common stock from our June 2020 equity follow-on offering and $4.4 million received under the Restated Credit Facility.

As of ~~September~~March 3031, ~~2021~~2022, we had borrowed $20.0 million under the ~~loan and security agreement, or~~ Credit Facility, with Hercules Capital, Inc., or Hercules. InWe ~~January~~made ~~2020~~interest-only payments through June 2021 and the first principal and interest payment on July 1, we2021. ~~entered~~The ~~into~~Credit anFacility was subsequently amended in July 2021 and ~~restated~~December ~~credit~~2021 ~~facility~~to extend the interest-only payment period through August 2022, orat which point we will be obligated to repay the principal balance and interest on the advances in equal monthly installments through December 2022. In January 2020, we entered into the Restated Credit Facility, ~~with Hercules,~~ which provides for borrowings of up to an additional $100.0 million in three tranches, subject to certain terms and conditions. As of ~~September~~March 3031, ~~2021~~2022, we had borrowed $5.0 million under the Restated Credit Facility. ~~The~~With ~~Credit~~the ~~Facility~~FDA ~~was~~approval ~~subsequently~~of ~~amended~~TAVNEOS in ~~July~~October 2021, ~~to extend~~ the interest-only payment period ~~through December 2021,~~ and ~~at which point we will then repay~~ the principal balance ~~and~~repayment ~~interest~~period onwas ~~the~~extended ~~advances~~through inMarch ~~equal~~1, ~~monthly~~2023 ~~installments~~and ~~through~~February ~~December~~ 1, ~~2022.~~2025, ~~See “Note 6~~respectively. ~~Long-term~~We ~~Debt”~~are inobligated ~~the Notes~~ to ~~Condensed~~pay ~~Consolidated~~an ~~Financial~~end ~~Statements included in Item 1~~ of ~~this Quarterly Report on Form 10-Q for additional information regarding our borrowings.~~

As of September 30, 2021, we had approximately $372.5 million in cash, cash equivalents, restricted cash and investments. We believe that our available cash, cash equivalents and investments will be sufficient to fund our anticipated level of operations for at least 12 months following our financial statement issuance date, November 9, 2021. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. 25

term charge of $1.3 million in December 2022. See “Note 6. Long-term Debt” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our borrowings.

As of March 31, 2022, we had approximately $372.9 million in cash, cash equivalents, restricted cash and investments. We believe that our available cash, cash equivalents, restricted cash and investments will be sufficient to fund our anticipated level of operations and capital expenditures for at least 12 months following issuance of our financial statement. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.

Our future capital requirements are difficult to forecast and will depend on many factors, including:

•

the ~~commercialization~~continuing sales of TAVNEOS as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis;

•

Vifor and any sublicensees’ ability to successfully commercialize and launch TAVNEOS and royalties therefrom;

•

the terms and timing of any other collaborative, licensing and other arrangements that we may establish;

•

the initiation, progress, timing and completion of preclinical studies and clinical trials for our drug candidates and potential drug candidates, including any delays as a result of the COVID-19 pandemic on our business, preclinical studies or clinical trials;

•

the number and characteristics of drug candidates that we pursue;

•

the progress, costs and results of our clinical trials;

•

delays that may be caused by changing regulatory approvals;

the outcome, timing and cost of regulatory approvals;

•

delays that may be caused by regulatory timelines and outcomes;

•

the cost and timing of hiring new employees to support continued growth and expansion;

•

the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;

•

25the cost and timing of procuring clinical and commercial supplies of our drug candidates and TAVNEOS;

•

the cost and ~~timing~~effectiveness of ~~procuring~~sales, ~~clinical~~marketing and ~~commercial~~distribution ~~supplies of our drug candidates~~functions; and

•

the ~~cost~~extent ~~and~~to ~~timing~~which ofwe ~~establishing~~acquire ~~sales~~or invest in businesses, ~~marketing~~drug ~~and~~candidates ~~distribution~~or ~~capabilities;~~products ~~and~~or technologies.

the extent to which we acquire or invest in businesses, drug products or technologies.

Contractual Obligations and Commitments

There have been no material changes outside the ordinary course of our business to the contractual obligations we reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 1, 2021.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements (as defined by applicable SEC regulations) that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources, except warrants and stock options.

Recent Accounting Pronouncements

See “Note 2. Summary of Significant Accounting Policies” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q ~~for a full description of recently issued accounting pronouncements, including the respective expected dates of adoption and effects on our consolidated financial position and results of operations~~.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our market risks at ~~September~~March 3031, ~~2021~~2022 have not changed significantly from those discussed in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, filed with the SEC on March 1, ~~2021~~2022, other than the following:

We are affected by market risk exposure primarily through the effect of changes in interest rates on amounts payable under the Credit Facility and Restated Credit Facility. At ~~September~~March 3031, ~~2021~~2022, borrowings under the Credit Facility totaled $20.0 million with an interest rate of 8.05%. Advances under the Credit Facility bear an interest rate equal to the greater of (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal, or Prime Rate, minus 4.75%, and (ii) 8.05%. We made interest-only payments on our borrowings under the Credit Facility through June 2021 and the first principal and interest payment on July 1, 2021. The Credit Facility was subsequently amended in July 2021 and December 2021 to extend the interest-only payment period through ~~December~~August ~~2021~~1, at2022, ~~which~~and ~~point we~~ will then ~~be obligated to~~ repay the principal balance and interest on the advances in equal monthly installments through December 1, 2022.

In addition, borrowings under the Restated Credit Facility totaled $5.0 million at ~~September~~March 3031, ~~2021~~2022 with an interest rate equal to the greater of (i) 8.50% plus the Prime Rate minus 5.25%, and (ii) 8.50%, which may be reduced upon the Company achieving certain cumulative net TAVNEOS revenue levels. We are obligated to make interest-only payments on our borrowings under the Restated Credit Facility through ~~September~~February 1, ~~2022~~2023, atand ~~which point we~~ will then ~~be obligated to~~ repay the principal balance and interest on the advances in equal monthly installments ~~after the interest-only period and continuing~~ through February 1, ~~2024~~2025. If the total amounts outstanding under the Credit Facility and the Restated Credit Facility remained at this level for an entire year and the interest rates increased by 1%, our annual interest expense would increase by an additional $250,000. See “Note 6. Long-term Debt” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our borrowings.

additional $250,000. See “Note 6. Long-term Debt” in the Notes to Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our borrowings.

Item 4. Controls and Procedures

Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

As of ~~September~~March 3031, ~~2021~~2022, management, with the participation of our Disclosure Committee, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial and Administrative Officer, to allow timely decisions regarding required disclosures.

26Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based on this evaluation, our Chief Executive Officer and Chief Financial and Administrative Officer concluded that, as of March 31, 2022, the design and operation of our disclosure controls and procedures were effective.

Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based on this evaluation, our Chief Executive Officer and Chief Financial and Administrative Officer concluded that, as of September 30, 2021, the design and operation of our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended ~~September~~March 3031, ~~2021~~2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. As a result of the COVID-19 pandemic, including the related stay-at-home and shelter-in-place orders mandated by state and local governments in which we operate, many of our employees have been working remotely since March 2020. As part of our Company’s transition to a temporary remote workforce, we took precautionary actions to re-evaluate our financial reporting process to provide assurance that we could report our financial results accurately and timely. We will continue to monitor and assess new potential impacts of the COVID-19 pandemic, including those related to any stay-at-home and shelter-in-place requirements, on the design and operating effectiveness of our internal controls going forward.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The Company and its Chief Executive Officer were named as defendants in two putative shareholder class actions filed on May 5, 2021, and June 8, 2021, in the U.S. District Court for the Northern District of California. These cases have been consolidated into the lead case, Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343-JST (N.D. Cal.) (the “Homyk action”). The Homyk action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act in connection with statements regarding ~~our~~the New Drug Application, or NDA, for TAVNEOS, and ~~seeks~~the underlying Phase III clinical trial, seeking an award of damages, interest and attorneys’ fees. A lead plaintiff ~~has~~was ~~not~~selected ~~yet~~on ~~been~~January ~~selected.~~28, We2022, ~~intend~~and toa ~~file~~consolidated aamended complaint was filed on March 28, 2022. The Company’s motion to dismiss these claims will be filed on May 19, 2022 and heard sometime after August 3, 2022, when the ~~complaint~~motion is fully briefed. In addition, the Company, the Board of Directors and certain of our officers were named as defendants in a putative shareholder derivative action filed on January 25, 2022, in the U.S. District Court for the Northern District of California, Napoli v. Schall, 3:22-cv-00499 (N.D. Cal) (the “Napoli action”). On March 11, 2022, the Court entered a stipulation staying the Napoli action until judgment is entered in the Homyk action. The Company plans to vigorously defend against ~~these~~both ~~claims~~actions. Given the early stages of ~~these~~both cases, wethe ~~are~~Company is unable to estimate a reasonably possible range of loss, if any, that may result from ~~the~~either litigation.

Item 1A. Risk Factors

There have been no material changes to the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, filed with the SEC on March 1, ~~2021~~2022, except the following:

~~Risks~~We ~~Related~~are subject to ~~Our~~a ~~Business~~securities class action lawsuit and a shareholder derivative action, and could become involved in furthersecurities class action or derivative litigation in the future that could divert management’s attention and adversely affect ourbusiness and could subject us to significant liabilities. If an unfavorable ruling were to occur, the litigation could have a materialadverse impact.

WeThe ~~are~~stock ~~substantially~~markets ~~dependent~~have from time-to-time experienced significant price and volume fluctuations that have affected the market prices for the shares of biotechnology and pharmaceutical companies. These broad market fluctuations as well a broad range of other factors, including the realization of any of the risks described in the “Risk Factors” section of our Annual Report on Form 10‐K for the fiscal year ended December 31, 2021, may cause the market price of the shares of our ~~ability~~common stock to ~~successfully~~decline. ~~commercialize~~In ~~TAVNEOSTM~~the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies generally experience significant share price volatility. Litigation often is expensive and diverts management’s attention and resources, which could adversely affect our business. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. We are presently involved and may become involved in this type of litigation in the future. As of the date of this filing, a consolidated securities class action (~~avacopan~~Homyk v. ChemoCentryx, Inc., 4:21-cv-03343-JST (N.D. Cal.)) and a shareholder derivative action (Napoli v. Schall, ~~which~~3:22-cv-00499 is(N.D. ~~currently~~Cal)) have been filed against us and/or certain of our ~~only~~officers ~~approved~~and ~~drug~~directors. ~~product~~The shareholder derivative action is stayed pending entry of judgment in the consolidated securities class action. IfGiven the early stage of these cases, we are unable to ~~successfully~~estimate ~~commercialize~~a ~~TAVNEOS,~~range ~~our~~of ~~ability~~potential toloss. ~~generate~~An ~~revenue~~unfavorable ~~and~~ruling ~~our~~in ~~financial~~either ~~condition~~lawsuit ~~will~~could behave ~~adversely~~a ~~affected~~materially adverse impact on us.

We have invested a substantial amount of capital resources on the development, registration and commercialization of TAVNEOS, which was approved in the United States in October as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis, or GPA, and microscopic polyangiitis, or MPA, the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use, and was approved in Japan in September for the treatment of patients with MPA and GPA. We cannot be certain that TAVNEOS will be successfully commercialized.

Our ability to generate revenue from drug product sales depends heavily on our success in many areas, including but not limited to:

successfully commercializing TAVNEOS, either independently or with marketing service providers;

the effectiveness of our sales and marketing strategy and operations, and obtaining market acceptance of TAVNEOS, including garnering market share from existing and future treatment alternatives;

maintaining compliance with all regulatory requirements applicable to TAVNEOS and our commercial activities, including the post-marketing requirements and post-marketing commitments required by the FDA;

obtaining coverage and adequate reimbursement from third-party payors for each of our drug products;

the continued acceptability of the safety profile of TAVNEOS and the occurrence of any unexpected side effects, adverse reactions or misuse, including potential business impact such as the need to withdraw the drug product (either voluntarily or as mandated by the FDA), loss of support by the advocacy communities or loss of positive corporate reputation resulting in related unfavorable media coverage in these areas;

successfully managing third-party service providers involved in the manufacturing and development of TAVNEOS;

successfully completing the development of TAVNEOS in other indications by demonstrating safety, tolerability and efficacy profiles that are satisfactory to the FDA and other regulatory bodies in other territories;

obtaining regulatory approvals to market TAVNEOS for other indications;

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;

maintaining, protecting and expanding the portfolio of intellectual property rights, including patents, trade secrets and know how; and

attracting, hiring and retaining qualified personnel.

In our efforts to market TAVNEOS in the United States for the adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, our revenue will be dependent, in part, on the size of the markets in the United States, or in other territories where we may seek and obtain regulatory approval, the number of competitors in such markets, the acceptance of the price of the drug

product in those markets and the ability to obtain reimbursement at any price. If the number of our addressable patients is not as large as we estimate or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such drug products. If we are not able to generate substantial revenue from the sale of approved drug product, we may never become profitable.

The commercial adoption of TAVNEOS and any other drug candidates we develop will depend on the degree of their market acceptance.

Even with the requisite approvals from the FDA and other regulatory authorities, the commercial adoption of TAVNEOS in the United States for the adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically GPA and MPA in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use, and in Japan for the treatment of patients with MPA and GPA, and any other indications and drug candidates we may develop, will depend on the degree of their acceptance by physicians, patients, third-party payors and others in the medical community. If TAVNEOS or any other drug candidates we develop do not achieve an adequate level of market acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of TAVNEOS or any other drug candidates we develop, if approved for commercial sale, will depend on a number of factors, some of which are beyond our control, including:

the safety and efficacy of the drug candidate as demonstrated in clinical trials;

the perception of physicians, patients, third-party payors and others in the medical community of the relative safety, efficacy, convenience, effect on quality-of-life and cost-effectiveness of the drug product, compared to those of other available treatments;

the drug product’s approved labeling, including the description of the drug product’s approved indications, the description of its efficacy, including the endpoints in which it showed an improvement, and the prevalence and severity of any side effects, including any associated limitations or warnings;

the cost of treatment in relation to alternative treatments, including any similar generic treatments;

our ability to differentiate TAVNEOS or other approved drug products from other treatments in the same space;

the prevalence and severity of any side effects, including those that may be discovered following approval and commercialization;

the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments;

the strength of marketing and distribution support and timing of market introduction of competitive drug products;

the publicity concerning our drug products or competing drug products and treatments;

drug product liability litigation alleging injuries relating to our drug products or similar classes of drugs;

any post-approval study requirements for our drug products and the results thereof; and

sufficient third-party insurance coverage and reimbursement.

Our continuing efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits and risks of TAVNEOS may require significant resources and may never be successful. Physicians may opt to prescribe the drug products of our competitors for a variety of reasons. If TAVNEOS fails to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.

We cannot guarantee that TAVNEOS or any other drug candidates we may seek to develop will ever be commercially successful, and to the extent they are not commercially successful, such drug candidates would incur significant expense with lower than expected or no corresponding revenue. Because we expect the sales of TAVNEOS to generate substantially all of our revenue for the foreseeable future, the failure of TAVNEOS to find market acceptance would substantially harm our business and could require us to seek additional financing.

The market opportunity for TAVNEOS or any future drug candidate we develop may be smaller than we estimate.

The potential market opportunity for TAVNEOS and any future drug candidate is difficult to precisely estimate. Our estimates of the potential market opportunity for our drug candidates include several key assumptions of the current market size and current pricing for commercially available drug products and are based on industry and market data obtained from industry publications, studies conducted by us, our industry knowledge, third-party research reports and other surveys. While we believe our estimates are reasonable and reliable, they may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of diseases and disorders. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for TAVNEOS or any future drug candidate we develop may be limited or may not be amenable to treatment with

TAVNEOS or such future drug candidate, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.

We have only recently begun product sales and anticipate that we will continue to incur significant losses for the foreseeable future, and if we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.

Other than TAVNEOS, we do not currently have any drug products approved for sale, and we continue to incur significant research and development and general and administrative expenses related to our operations. Our net loss for the years ended December 31, 2020, 2019 and 2018 was $55.4 million, $55.5 million and $38.0 million, respectively. As of December 31, 2020, we had an accumulated deficit of $485.3 million. We expect to continue to incur significant losses for the foreseeable future. We expect these losses and our cash utilization to increase in the near term as we continue to conduct clinical trials for CCX559 and CCX507 and conduct research and development of our other drug candidates. To date, substantially all of our revenues has been derived from upfront fees and milestone payments, other payments pursuant to our collaboration agreements and government grants and contracts for research and development. For example, in May 2016 and December 2016, we entered into collaboration and license agreements with Vifor (International) Ltd. and/or its affiliates, or collectively, Vifor, for the commercialization of avacopan and CCX140, respectively. In addition, if approved, we expect to incur significant costs to commercialize our drug products and our drug products may never gain market acceptance. If our drug candidates fail to demonstrate safety and efficacy in clinical trials, do not gain regulatory approval, or do not achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. Because of the numerous risks and uncertainties associated with developing pharmaceutical drugs, we are unable to predict the extent of any future losses or whether we will become profitable.

If we are unable to obtain regulatory approval to market our drug products in the United States and foreign jurisdictions, we will not be permitted to commercialize such drug products.

We have received regulatory approval for TAVNEOS as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically GPA and MPA in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use, pursuant to a new drug application, or NDA, that was approved by the FDA in October 2021. Before receiving regulatory approval to market any other drug product, we must demonstrate with substantial clinical evidence to the satisfaction of the FDA or other regulatory authority that the drug product is safe and effective in the patient population and the indication that will be treated. Data obtained from preclinical and clinical activities are susceptible to varying interpretations that could delay, limit or prevent regulatory approvals. In addition, delays or rejections may be encountered based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of drug products, total or partial suspension of production or injunction, adverse publicity, as well as other regulatory action against our potential drug products or us.

If regulatory approval of a drug product is granted, such approval will be limited to those indications or disease states and conditions for which the drug product is demonstrated through clinical trials to be safe and effective. For example, TAVNEOS has only been approved in the United States as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, and our marketing of TAVNEOS must be consistent with the approved indication. We cannot assure you that any drug product developed by us, alone or with others, will be demonstrated to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive regulatory approval.

Outside the United States, our ability, or that of our collaborative partners, to market a drug product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks and costs associated with FDA approval described above and may also include additional risks and costs, such as the risk that such foreign regulatory authorities, which often have different regulatory and clinical trial requirements, interpretations and guidance from the FDA, may require additional clinical trials or results for approval of a drug candidate, any of which could result in delays, significant additional costs or failure to obtain such regulatory approval. For example, there can be no assurance that we or our collaborative partners will not have to provide additional information or analysis, or conduct additional clinical trials, before receiving approval to market drug candidates.

TAVNEOS has been approved by the FDA as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use. Regulatory approval is limited by the FDA to the specific indication for which approval has been granted and, unless we seek regulatory approval for additional indications, we will be prohibited from marketing TAVNEOS for other indications. We may be subject to fines, penalties or injunctions if we are determined to have promoted or be promoting the use of TAVNEOS for unapproved, or “off-label” uses, resulting in damage to our reputation and business.

While we received approval for TAVNEOS from the FDA for the indication of adjunctive treatment for adult patients with severe active ANCA-associated vasculitis in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use. TAVNEOS is not indicated to treat any other conditions. We are prohibited from promoting TAVNEOS for any

other indication unless we are granted FDA approval for such indication. The FDA strictly regulates the promotional claims that may be made about prescription drug products, and TAVNEOS may not be promoted for uses that are not approved by the FDA as reflected in its approved labeling. If we are not able to obtain FDA approval for any desired future indications for our drug products and drug candidates, our ability to effectively market and sell our drug products may be reduced and our business may be adversely affected.

While physicians may choose to prescribe drug products for uses that are not described in the drug product’s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the drug products for indications that are not specifically approved by the FDA. These “off-label” uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biotechnology or pharmaceutical companies on unapproved uses. If the FDA determines that our promotional activities constitute promotion of an unapproved use of our products, it could request that we modify our promotional materials and subject us to FDA regulatory or enforcement actions as well as actions by other agencies, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved drug product from the market, mandatory or voluntary recalls, civil fines, disgorgement of money, operating restrictions, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement, injunctions or criminal prosecution, any of which could significantly harm our business.

Even though we have obtained regulatory approval for TAVNEOS, and even if we obtain approval for any of our other drug candidates, we or our collaborative partners will still face extensive regulatory requirements and our drug products may face future development and regulatory difficulties.

Even though we have obtained regulatory approval for TAVNEOS, and even if we obtain regulatory approval for any of our other drug candidates, our drugs and manufacturing operations will remain subject to continual review by the FDA, the EMA and EU Member State Competent Authorities, and/or non-U.S./non-EU regulatory authorities. Any regulatory approval that we receive for our drug candidates may be subject to limitations on the indicated uses for which the drug product may be marketed or contain requirements for potentially costly post-marketing follow-up studies to monitor the safety and efficacy of the drug product. The FDA and the EMA also have authority to require a risk evaluation and mitigation strategy, or REMS, or risk management plan, as part of an NDA, CMA, marketing authorization application, or MAA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring treated patients to enroll in a registry. In addition, upon approval by the FDA, the EMA, EU Member State Competent Authorities, and/or non-U.S./non-EU regulatory authorities of any of our drug candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA, the EMA, EU Member State Competent Authorities, and other regulatory authorities with regard to the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for our drug products. The FDA and the EMA, the European institutions and the EU Member State Competent Authorities, strictly regulate the promotional claims that may be made about prescription drug products. In particular, a drug product may not be promoted for uses that are not approved by the FDA or the European Commission as reflected in the drug product's approved labeling. For example, TAVNEOS was approved by the FDA in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use. Even though we have obtained approved for TAVNEOS in this indication, and even if we receive regulatory approval for any of our other drug candidates, physicians may nevertheless prescribe our drugs to their patients in a manner that is inconsistent with the approved label. However, if we are found to have promoted such unapproved uses, we may become subject to significant liability and government fines.

In addition, manufacturers of drug products are required to comply with cGMP regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must authorize manufacturing facilities before they can be used to manufacture our drug products, and such facilities will remain subject to continual review and periodic inspections by the FDA, the EMA, EU Member State Competent Authorities, and other regulatory authorities for compliance with cGMP regulations.

If we or a regulatory authority discovers previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug product is manufactured, a regulatory authority may impose restrictions on that drug product, the manufacturer or us, including imposition of a REMS, or similar risk management measures, or requesting recall or withdrawal of the drug product from the market or suspension of manufacturing. If we, our drug products or the manufacturing facilities for our drug products fail to comply with regulatory requirements of the FDA, the EMA, the EU institutions, the EU Member State Competent Authorities and/or other non-U.S./non-EU regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:

warning letters, untitled letters or other communications asserting that we are in violation of law;

injunctions, civil or criminal penalties or monetary fines;

suspension or withdrawal of regulatory approvals;

suspension of ongoing clinical trials;

restrictions on operations, including costly new manufacturing requirements;

refusal to approve pending applications seeking regulatory approval for new drugs or supplements to approved applications submitted by us;

product recalls;

drug product detentions or seizures; or

refusal to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may delay or inhibit our ability to successfully commercialize our drug products and generate revenues.

The regulatory requirements and policies may change and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States, the EU or in other countries or jurisdictions. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we will not be permitted to market our future drug products and our business will suffer.

Undesirable side effects caused by TAVNEOS could impact our ability to market and derive revenue from TAVNEOS, and such side effects or adverse events associated with any drug candidate could compromise our ability to develop our drug candidates.

As we commercialize TAVNEOS or conduct additional clinical trials on TAVNEOS or our other drug candidates, these efforts could reveal a high and unacceptable incidence and severity of undesirable side effects. Undesirable side effects could adversely affect patient enrollment in clinical studies, cause us or regulatory authorities to interrupt, delay or halt clinical studies or result in the delay, denial or withdrawal of regulatory approval by the FDA or other regulatory authorities. Undesirable or adverse side effects also could result in regulatory authorities mandating a more restrictive prescribing label for the drug product, which, in turn, could limit the market acceptance of the drug product even if approved for marketing and commercialization.

Drug-related side effects could result in potential product liability claims. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations, business and financial condition. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, significant negative media attention, withdrawal of clinical study participants, costs due to related litigation, distraction of management’s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our current drug candidate or any future drug candidate, product recalls, restrictions on labeling, marketing or promotion, decreased demand for our drug candidates, if approved for marketing, and loss of revenue.

Additionally, if we or others later identify undesirable side effects caused by either TAVNEOS or any other drug candidate, either in the post-marketing setting or in clinical trials, a number of potentially significant negative consequences could result, including but not limited to:

the delay, prevention or withdrawal of approvals by regulatory authorities;

the requirement of additional warnings on the prescribing label;

the requirement of a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;

litigation and the potential to be held liable for harm caused to patients;

the recall or withdrawal of the drug product;

fines, injunctions, or imposition of civil or criminal penalties; and

an adverse effect on our reputation.

Any of these events could prevent us from achieving or maintaining market acceptance of TAVNEOS or any other drug candidate for which we obtain approval, and could significantly harm our business, results of operations, financial condition and prospects.

We are in the early stages of developing our commercialization infrastructure in the United States. If we are unable to develop a sales and marketing and distribution capability on our own or through collaborations with marketing partners, we will not be successful in commercializing our future drug products.

We are in the early stages of developing our commercialization infrastructure in the United States and have no history of selling, marketing or distributing therapeutic drugs. In order to market any drugs that may be approved by the FDA, EMA or other comparable regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities, or make arrangements with third parties to perform these services. We have entered into the Avacopan Agreement with Vifor for development and commercialization of avacopan outside of the United States and Vifor has in turn sublicensed its right to commercialize avacopan in Japan to its sublicensee Kissei. We retain commercialization rights to avacopan in the United States. To the extent we rely directly or indirectly on third parties such as Vifor for marketing and distributing our approved drug products, any revenue we receive will depend upon the efforts of third parties, which may not be successful and are only partially within our control and our drug product revenue is likely to be lower than if we directly marketed or sold our drug products. Future collaborators may fail to develop or effectively commercialize our drug candidates because they cannot obtain necessary regulatory approvals, development or commercialization is not commercially reasonable, they elect to pursue competitive drug products outside of the collaboration, or for other reasons. If we are unable to enter into arrangements with third parties to commercialize any approved drug products on acceptable terms or at all, we may not be able to successfully commercialize our future drug products or we will have to market these drug products ourselves, which will be expensive and require us to build our own commercial infrastructure, which we do not have experience doing. We cannot assure you we will be successful in any of these initiatives. If we are not successful in commercializing our future drug products, either on our own or through collaborations with third parties, any future drug product revenue will be materially adversely affected.

The development of new drugs is a highly risky undertaking which involves a lengthy process, and our drug discovery and development activities therefore may not result in drug products that are approved for marketing and sale by the applicable regulatory authorities on the time schedule we have planned, or at all, or result in substantial payments to us.

Although we have obtained regulatory approval for TAVNEOS in the United States, many of our drug candidates are in the early stages of drug discovery or clinical trials or, with respect to TAVNEOS, are in research programs for potential additional indications, and are prone to the risks of failure inherent in drug development. We will need to conduct significant additional preclinical studies and clinical trials for many of our drug candidates before we can demonstrate that such drug candidates are safe and effective to the satisfaction of the FDA, the EMA and other regulatory authorities. Preclinical studies and clinical trials are expensive and uncertain processes that take years to complete. For example, we incurred significant expenses related to the IND filing and the completed single ascending dose Phase I clinical trial for CCX915, our first generation CCR2 drug candidate, which did not advance into Phase II clinical trials because its pharmacokinetic, or PK, properties in humans did not meet our expectations. Failure can occur at any stage of the process, and we cannot assure you that any of our drug candidates will demonstrate safety and efficacy in clinical trials or result in commercially successful drug products. While we have filed integrated regulatory submissions in 2020 with the EMA and FDA for regulatory approval of TAVNEOS, and while we received approval from the FDA in October 2021, we can provide no assurance we will receive such approval in Europe.

We cannot assure you that our ongoing clinical trials or any future clinical trial of any of our other drug candidates will be completed on schedule, or at all, or whether our planned clinical trials will start in a timely manner. The commencement of our planned clinical trials could be substantially delayed or prevented by a number of factors, including:

delays or failures in obtaining sufficient quantities of the API and/or drug product;

delays or failures in reaching agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites;

delays or failures in obtaining institutional review board, or IRB, or ethics committee approval to conduct a clinical trial at a prospective site;

the need to successfully complete, on a timely basis, preclinical safety pharmacology or toxicology studies;

the limited number of, and competition for, suitable sites to conduct the clinical trials;

the limited number of, and competition for, suitable patients for enrollment in the clinical trials;

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies; or

obtaining regulatory authorizations to commence a trial.

The completion of our clinical trials could also be substantially delayed or prevented by a number of factors, including:

changes to clinical trial protocols;

slower than expected rates of patient recruitment and enrollment;

failure of patients to complete the clinical trials;

failure of our third party vendors to timely or adequately perform their contractual obligations relating to the clinical trials or in accordance with regulatory requirements;

inability or unwillingness of patients or medical investigators to follow our clinical trial protocols;

inability to monitor patients adequately during or after treatment;

termination of the clinical trials by one or more clinical trial sites;

unforeseen safety issues;

occurrence of serious adverse events in trials of the same class of agents conducted by other companies;

subjects choosing an alternative treatment for the indication for which we are developing our drug candidates, or participating in competing clinical trials;

selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;

lack of efficacy demonstrated during clinical trials;

lack of adequate funding to continue the clinical trials;

the need for unexpected discussions with the FDA, EMA or other foreign regulatory agencies regarding the scope or design of our clinical trials or the need to conduct additional trials;

unforeseen delays by the FDA, EMA or other foreign regulatory agencies after submission of our results;

a facility manufacturing our drug candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down; any changes to our manufacturing process that may be necessary or desired;

any changes to our manufacturing process that may be necessary or desired; or

third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.

We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or ethics committees of the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Any failure or significant delay in completing clinical trials for our drug candidates would harm the commercial prospects for our drug candidates and adversely affect our financial results.

Additionally, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to regulatory agencies and ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our drug candidates may be harmed and our ability to generate drug product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a drug candidate.

If we are required to suspend or discontinue clinical trials due to side effects or other safety risks, or if we obtain unfavorable results in our post-marketing studies of TAVNEOS or any future studies of the long-term effects associated with the use of our drug candidates, our efforts to commercialize our drug products could be delayed or halted.

Our clinical trials may be suspended or terminated at any time for a number of safety-related reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that our drug candidates present an unacceptable safety risk to the clinical trial patients. In addition, IRBs or regulatory agencies may order the temporary discontinuation or termination of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, including if they present an unacceptable safety risk to patients. Administering any drug candidate to humans may

produce undesirable side effects. The existence of undesirable side effects resulting from our drug candidates could cause us or regulatory authorities, such as the FDA, to interrupt, delay or halt clinical trials of our drug candidates and could result in the FDA or other regulatory agencies denying further development or approval of our drug candidates for any or all targeted indications.

Further, chemokine receptors and chemoattractant receptors are a novel class of targets. As a result, we may experience unforeseen adverse side effects with our existing and future drug candidates for such targets, including TAVNEOS and CCX507. As of the date of this Quarterly Report on Form 10-Q, nine of our drug candidates have been tested in human beings. Although we have not observed material safety concerns in prior studies of our drug candidates, later trials could reveal unforeseen adverse events. The safety PK results from preclinical studies may not be indicative of results observed in subsequent clinical trials. We have not completed studies on the long-term effects associated with the use of our drug candidates. Completion of studies of these long-term effects may be required for regulatory approval and would delay our introduction of our drug candidates into the market. These studies could also be required at any time after regulatory approval of any of our drug candidates. Absence of long-term data may also limit the approved uses of our drugs, if any, to short-term use. Some or all of our drug candidates may prove to be unsafe for human use.

Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable regulatory authorities. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential drug product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Given the serious nature of the conditions we are treating in our clinical trials, and the multiple concomitant medications including our active drug candidates that our patients are treated with, side effects (such as nausea, diarrhea, infections, hepatic enzyme elevations, and possible allergic reactions) have been reported in our clinical studies. While such disorders may be found to be not related to our drug candidates, such events may create a negative safety perception. Even if any of our drug candidates receives regulatory approval, as greater numbers of patients use a drug following its approval, an increase in the incidence or severity of side effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result in a number of potentially significant negative consequences, including that regulatory authorities may withdraw their approval of the drug, regulatory authorities may require the addition of labeling statements, such as “black box” warnings or contraindications, or impose additional safety monitoring or reporting requirements, we may be required to change the way the drug is administered or conduct additional clinical trials, we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients, we could be sued and held liable for harm caused to patients, and our reputation may suffer. Any of these events could substantially increase the costs and expenses of developing, commercializing and marketing any such drug candidates or could harm or prevent sales of any approved drug products.

Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.

We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.

If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our drug products may be harmed, which could harm our business, operating results, prospects or financial condition.

Even though we have obtained orphan drug designation to TAVNEOS in the United States, Japan and Europe, we may not be able to obtain or maintain orphan drug exclusivity for this drug candidate or any other drug candidates for which we obtain orphan drug designation.

In the United States, under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition. Such diseases and conditions are those that affect fewer than 200,000 individuals in the United States, or if they affect more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug available in the United States for these types of diseases or conditions will be recovered from sales of the drug. Orphan drug designation must be requested before submitting an NDA. If the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by that agency. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, but it can lead to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers.

If a drug that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the drug is entitled to orphan drug marketing exclusivity for a period of seven years. Orphan drug marketing exclusivity generally prevents the FDA from approving another application, including a full NDA, to market the same drug or biological product for the same indication for seven years, except in limited circumstances, including if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. For purposes of small molecule drugs, the FDA defines “same drug” as a drug that contains the same active chemical entity and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug marketing exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Orphan drug marketing exclusivity rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

The criteria for designating an orphan medicinal drug in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal drug may be designated as orphan if (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the drug, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the drug product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

The ten-year market exclusivity in the EU may be reduced to six years if, at the end of the fifth year, it is established that the drug product no longer meets the criteria for orphan designation, for example, if the drug product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar drug product for the same indication at any time if:

the second applicant can establish that its drug product, although similar, is safer, more effective or otherwise clinically superior;

the applicant consents to a second orphan medicinal application; or

the applicant cannot supply enough orphan medicinal product.

The FDA granted orphan drug designation for TAVNEOS for the treatment of C3G and ANCA-associated vasculitis, including GPA, formerly known as Wegener’s granulomatosis, MPA and Churg-Strauss syndrome. Upon approval of TAVNEOS by the FDA as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoid use, the FDA granted us orphan drug exclusivity in this indication, which means that the FDA cannot approve the same drug for the same indication for a period of seven years, except where a subsequent applicant for the same drug demonstrates that its product is clinically superior to TAVNEOS or we otherwise are unable to assure sufficient quantities. In November 2014, the European Commission granted orphan drug designation for avacopan for the treatment of GPA and MPA, and, in June 2017, for the treatment of C3G. However, we cannot assure you that we will be able to maintain orphan drug exclusivity for TAVNEOS or that we will be able to obtain or maintain orphan drug exclusivity for any of our other drug candidates, if they are approved for any orphan-designated use in any jurisdiction, in a timely manner or at all, or that a competitor will not obtain orphan drug exclusivity that could block the regulatory approval of any of our drug candidates for several years. If we are unable to maintain or obtain orphan drug exclusivity, our ability to generate sufficient revenues may be negatively affected. If a competitor is able to obtain orphan drug exclusivity that would block our drug candidates’ regulatory approval, our

ability to generate revenues would be significantly reduced, which would harm our business prospects, financial condition and results of operations.

We rely on third party contract manufacturing organizations to manufacture and supply TAVNEOS and our drug candidates for us. If one of our suppliers or manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers. We may also face delays in the development and commercialization TAVNEOS or any of our drug candidates.

We currently have limited experience in, and we do not own facilities for, manufacturing TAVNEOS or our drug candidates. We rely upon third party contract manufacturing organizations to manufacture and supply larger quantities of TAVNEOS and these other drug candidates. The manufacture of pharmaceutical products in compliance with cGMP requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the drug candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced FDA cGMP requirements, other federal and state regulatory requirements, and foreign regulations. Raw materials for the synthesis of our API are sourced globally. If the manufacturers of our raw materials and pharmaceutical products were to encounter any difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study drugs in our preclinical studies and clinical trials would be jeopardized. Any delay or interruption in the supply of preclinical study or clinical trial materials could delay the completion of our preclinical studies and clinical trials, increase the costs associated with maintaining our preclinical study and clinical trial programs and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the studies and trials completely.

All manufacturers of our drug candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our component materials may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies at any time may also implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of drug products. We have little control over our manufacturers’ compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in drug product approval, product seizure or recall, or withdrawal of drug product approval. If the safety of any drug product supplied is compromised due to our manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our drug products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our drug candidates or entail higher costs or impair our reputation.

We currently rely on a single source supplier for API and drug product for each of our drug candidates. In the event that we and our suppliers cannot agree to the terms and conditions for them to provide some or all of our API clinical and commercial supply needs, or if any single source supplier terminates the agreement in response to a breach by us, or if a supplier is not able to timely provide us with API and drug product, we would not be able to manufacture the API on a commercial scale until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, TAVNEOS and our other drug candidates. For example, public health epidemics, such as the ongoing coronavirus outbreak, may impact the ability of our existing or future suppliers to provide us with preclinical study or clinical trial materials.

Although alternative sources of supply exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New suppliers of any API would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing such ingredients. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.

Risks Related to Government Regulation

The regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates.

The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drugs and drug candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States, the EMA, the EU institutions (e.g., the European Commission) and the EU Member State Competent Authorities, as well as equivalent authorities and regulatory bodies in other countries, which regulations differ from country to country. We are not permitted to market our drug candidates in the United States until we receive approval of an NDA from the FDA and in the EU until we have received approval from the European Commission or EU Member State Competent Authorities. Obtaining approval of an NDA, MAA or CMA can be

an expensive, time-consuming and uncertain process. In addition, failure to comply with FDA, EMA and other applicable U.S., EU and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including:

warning letters;

civil and criminal penalties;

injunctions;

withdrawal of approved drug products;

drug product seizure or detention;

drug product recalls;

total or partial suspension of production; and

refusal to approve pending NDAs or supplements to approved NDAs, pending CMA or MAAs.

Prior to receiving approval to commercialize any of our drug candidates in the United States, the EU, or in other countries, we must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA, the EMA, and other regulatory authorities abroad, that such drug candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our drug candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, and other regulatory authorities. Administering any of our drug candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials of our drug candidates and result in the FDA, the EMA, or other regulatory authorities denying approval of our drug candidates for any or all targeted indications.

Regulatory approval of an NDA or NDA supplement, or of a CMA, MAA, or of their respective extensions and variations, is not guaranteed, and the approval process is expensive and may take several years. The FDA and the EMA also have substantial discretion in the approval process. Despite the time and expense exerted, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA or EMA approval varies depending on the drug candidate, the disease or condition that the drug candidate is designed to address, and the regulations applicable to any particular drug candidate. The FDA or EMA can delay, limit or deny approval of a drug candidate for many reasons, including, but not limited to, the following:

a drug candidate may not be deemed safe or effective;

FDA or EMA officials may not find the data from preclinical studies and clinical trials sufficient;

the FDA or EMA might not approve our or our third-party manufacturer’s processes or facilities; or

the FDA or EMA may change its approval policies or adopt new regulations.

If any of our drug candidates fails to demonstrate safety and efficacy in clinical trials or does not gain regulatory approval, our business and results of operations will be materially and adversely harmed.

Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new drug products and services from being developed or commercialized in a timely manner, which could negatively impact our business.

The ability of the FDA to review and approve new drugs can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July 10, 2020, the FDA announced its intention to resume certain on-site

inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

New healthcare reform measures, or changes to existing laws and regulations, could hinder or prevent our drug candidates’ commercial success by making it difficult or impossible for us to obtain adequate prices or insurance coverage.

In the United States, there have been and we expect there will continue to be a number of legislative and regulatory changes to the healthcare system in ways that could affect our future revenues and profitability and the future revenues and profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, in March 2010, the Affordable Care Act was signed into law. It contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which impacted existing government healthcare programs and resulted in the development of new programs. The Affordable Care Act, among other things:

imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs” to specified federal government programs;

increased the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%;

required collection of rebates for drugs paid by Medicaid managed care organizations;

required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70% (in 2021) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; and

mandated a further shift in the burden of Medicaid payments to the states.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden had issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the healthcare reform measures of the Biden administration, or other efforts to challenge the ACA, if any, will impact the ACA or our business.

Other legislative changes have been adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. In January 2013, the ATRA was enacted, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Recently, there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed drug products, in part informed by the current atmosphere of mounting criticism of prescription drug costs in the U.S., which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. We expect there will continue to be legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell TAVNEOS profitably, as governmental oversight and scrutiny of pharmaceutical companies is increasing. We anticipate that the U.S. Congress, state legislatures, and regulators may adopt or accelerate adoption of new healthcare policies and reforms intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare, Medicaid and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs, and additional pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures. For example, measures have been introduced in Congress that would

impose caps on prescription drug prices and would require manufacturers to negotiate drug pricing with the government. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our potential customers and accordingly, our financial operations.

There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of health care. We cannot predict the initiatives that may be adopted in the future or their full impact, particularly in light of the current presidential administration and U.S. Congress. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of health care may adversely affect:

our ability to set a price we believe is fair for our drug products;

our ability to generate revenues and achieve or maintain profitability; and

the availability of capital.

Further, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. In light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Governmental Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the recall and withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products or require safety surveillance and/or patient education. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and the drug approval process. Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate or suspend clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more limited indication than originally sought.

Even if we are able to commercialize TAVNEOS or our other drug candidates, if approved, the drugs may become subject to unfavorable pricing regulations or third party reimbursement practices, which could harm our business.

Successful sales of TAVNEOS and our drug candidates, if approved, depend on the availability of adequate coverage and reimbursement from third-party payors. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new drug acceptance.

Our ability to commercialize any drugs successfully also will depend in part on the extent to which coverage and reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but be subject to price regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recover our investment in TAVNEOS or our drug candidates, even if our drug candidates obtain regulatory approval. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a drug is:

a covered benefit under its health plan;

safe, effective and medically necessary;

appropriate for the specific patient;

cost-effective; and

neither experimental nor investigational.

We cannot be sure that reimbursement will be available for TAVNEOS or any other drug that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop.

In the United States, no uniform policy of coverage and reimbursement for drugs exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a drug from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our drugs on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given drug, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of our drugs.

If we obtain approval in one or more non-U.S. jurisdictions for our drug candidates, we will be subject to rules and regulations in those jurisdictions. In some non-U.S. jurisdictions, the reimbursement of drugs and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining regulatory approval of a drug candidate. In addition, market acceptance and sales of our drug candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our drug candidates and may be affected by existing and future health care reform measures.

If we fail to comply with healthcare laws and regulations, we could face investigations, substantial civil or criminal penalties and our business, operations and financial condition could be adversely affected. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.

Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse rules by both the federal government and the states in which we conduct our business. The laws and regulations that may affect our ability to operate include, without limitation:

the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in significant civil monetary penalties or criminal fines and imprisonment. Violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid;

the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government including the Medicare and Medicaid or other federal healthcare programs. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with alleged “off-label” promotion of drugs, misstated government pricing information, or provision of free drug product or other items of value to customers, among other things. Private individuals can bring False Claims Act “qui tam” actions, on behalf of the government and such individuals, commonly known as “whistleblowers,” may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the federal civil False Claims Act, the government may impose significant civil fines and penalties, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;

federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;

the federal Physician Payments Sunshine Act, which requires pharmaceutical companies to submit annual reports to CMS. In the annual reports, pharmaceutical companies must report information related to payments and other transfers of value to teaching hospitals, physicians, and, beginning in 2022, certain other health care professionals. Failure to submit required information, or failure to submit information in a timely, accurate and complete manner, may result in significant civil monetary penalties;

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers or competitors; and

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by the government or, in some states, any payor including commercial insurers; state laws

that require pharmaceutical companies to comply with the industry’s voluntary compliance guidelines and the applicable compliance guidance published by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and drug product pricing information.

In addition, certain states mandate that we comply with a state code of conduct, adopt a company code of conduct under state criteria, disclose marketing payments made to physicians and other healthcare providers, and/or report compliance information to the state authorities. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply in multiple jurisdictions with different compliance and reporting requirements increases the possibility that a pharmaceutical company may run afoul of one or more of the requirements.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the exclusion from participation in U.S. federal or state health care programs and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it or reach a settlement agreement, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

Risks Related to the Securities Markets and an Investment in Our Stock

There may not be a viable market for our common stock or the price of our common stock may be volatile, and stockholders may not be able to sell their shares at prices that are attractive to them.

There was no public market for our common stock prior to our initial public offering in February 2012, the trading volume of our common stock on the Nasdaq Global Select Market has been limited and there can be no assurance that an active and liquid trading market for our common stock will develop or be sustained. We cannot predict the extent to which investor interest in our company will lead to the development or maintenance of an active trading market on the Nasdaq Global Select Market or otherwise or how liquid that market might become. If an active public market does not develop or is not sustained, it may be difficult for stockholders to sell their shares of common stock at prices that are attractive to them, or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or drugs, drug candidates or technologies by using our shares of common stock as consideration.

Stockholders may also be unable to sell their shares of common stock at prices that are attractive to them due to fluctuations in the market price of our common stock. The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile. Since the commencement of trading in connection with our initial public offering in February 2012, the publicly traded shares of our common stock have themselves experienced significant price and volume fluctuations. During the nine-month period ended September 30, 2021, the price per share for our common stock on the Nasdaq Global Select Market ranged from a low sale price of $9.53 to a high sale price of $70.29. This market volatility is likely to continue. These and other factors could reduce the market price of our common stock, regardless of our operating performance. In addition, the trading price of our common stock could change significantly, both over short periods of time and the longer term, due to many factors, including, but not limited to, those described elsewhere in this “Risk Factors” section and the following:

results from, and any delays in, clinical trial programs relating to our drug candidates, including the ongoing and planned clinical trials for TAVNEOS, CCX559, CCX507 and other drug candidates;

announcements of regulatory approvals or disapprovals of our drug candidates, or delays in any regulatory agency review or approval processes;

failure or discontinuation of any of our research programs;

announcements relating to future collaborations;

general economic conditions in the United States and abroad;

acquisitions and sales of new drug products, technologies or business;

delays in the commercialization of any of our drug candidates;

market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors;

the issuance of new or changed securities analysts’ reports or recommendations regarding us, our competitors or our industry in general;

actual and anticipated fluctuations in our quarterly operating results;

disputes concerning our intellectual property or other proprietary rights;

introduction of technological innovations or new drug products by us or our competitors;

manufacturing issues related to our drug candidates for clinical trials or future drug products for commercialization;

market acceptance of TAVNEOS or our future drug products;

the level of underlying demand for TAVNEOS and customers’ buying patterns

deviations in our operating results from the estimates of analysts, or other analyst comments;

third-party payor coverage and reimbursement policies;

new legislation in the United States relating to the sale or pricing of pharmaceuticals;

FDA, EMA or other U.S. or foreign regulatory actions affecting us or our industry;

drug product liability claims or other litigation or public concern about the safety of our drug candidates or future drugs;

our ability to obtain necessary intellectual property licenses;

the outcome of any future legal actions to which we are party;

sales of our common stock by our officers, directors or significant stockholders;

additions or departures of key personnel; and

other external factors, including natural disasters and other crises.

In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that have been often unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. As of the date of this filing, a consolidated securities class action lawsuit has been filed against us (Homyk v. ChemoCentryx, Inc., 4:21-cv-03343-JST (N.D. Cal.), and other litigation may be filed in the future. Given the early stage of this case, we are unable to estimate a range of potential loss. Furthermore, we may incur substantial costs defending the lawsuit and the attention of our management may be diverted from the operation of our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not Applicable.

Item 3. Defaults Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

Not Applicable.

Item 6. Exhibits

A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.

4329

EXHIBIT INDEX

ExhibitNumber		Description
10.1		First Amendment to Amended and Restated Loan and Security Agreement.
10.1#		Amended and Restated Non-Employee Director Compensation Policy.
31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
#		Indicates management contract or compensatory plan.

4430

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CHEMOCENTRYX, INC.
Date: November 9, 2021		/s/ Thomas J. Schall, Ph.D.
Date: May 10, 2022		/s/ Thomas J. Schall, Ph.D.
		Thomas J. Schall, Ph.D.President and Chief Executive Officer(Principal Executive Officer)
Date: November 9, 2021		/s/ Susan M. Kanaya
Date: May 10, 2022		/s/ Susan M. Kanaya
		Susan M. KanayaExecutive Vice President, Chief Financial and Administrative Officer and Secretary (Principal Financial and Accounting Officer)

4531

Filing Compare · ChemoCentryx, Inc.